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ABSTRACT
Cerebral Venous Thrombosis (CVT) is one of the rarest causes of stroke. It is described as complete or partial occlusion 
of the sinuses or cortical veins of the brain. A relationship between high altitude (HA) and cerebral venous thrombosis 
has been long suspected due to various case reports and studies, however, the exact underlying mechanisms and 
etiologies are highly complex and debatable. In this article review we discuss the incidence etiologies, risk factors, 
clinical presentations and management of CVT at high altitude. CVT majorly affects young people [2]. It presents with 
a wide variety of clinical presentations due to the complexity of cerebral venous architecture and a combination of 
edema, increased intracranial pressure and venous infarct. Numerous etiologies have been suggested for the 
incidence of CVT; varying from dehydration, increased blood viscosity leading to endothelial injury, immobility, 
inflammation, genetic expression of certain prothrombotic entities, triggering of the coagulation cascade, platelet 
dysfunction and underlying coagulation disorders. Individuals with history of coagulation abnormalities should be 
screened for underlying thrombophilias and cautiously ascend to higher altitudes. CVT should be considered in all 
neurological clinical presentations at high altitude. High altitude trekkers should be educated on how to keep hydrated 
and avoid immobility, exposure to extreme cold and seeking immediate help for symptoms like headache and disturbed 
mental status.
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R E V I E W  A R T I C L E
INTRODUCTION: CVT accounts for 1% of all strokes. 
Occurrence of CVT at high altitude is also a rare 
phenomenon, however, the numerous anecdotal 
records from the past and the recently documented 
case reports of CVT occurring in the context of high 
altitude have urged the scientific community to find 
plausible etiologies that help explain the underlying 
mechanisms involved. The exact prevalence of CVT at 
high altitude remains undiscovered due to the 
challenges faced at determining the risk factors and 
asymptomatic hypercoagulable states of climbers 
ascending to high altitudes [1]. The case reports that 
are available are few in number and without controls. 
CVT majorly affects young people [2]. It presents with a 
wide variety of clinical presentations due to the 
complexity of cerebral venous architecture and a 
combination of edema, increased intracranial pressure 
and venous infarct [2, 28]. The inconsistency in the 
clinical findings of CVT makes it immensely challenging 
to diagnose in the context of high altitude with several 
other commonly occurring conditions such as Acute 
Mountain Sickness or High Altitude Cerebral Edema 
being the much more probable causes. High Altitude is 
associated with increased propensity for developing a 
hypercoagulable state by multiple studies and case 
reports [5 -10]. Various etiologies have been suggested 
for the incidence of CVT; varying from dehydration, 
increased blood viscosity leading to endothelial injury, 
immobility, inflammation, genetic expression of certain 
prothrombotic entities, triggering of the coagulation 
cascade, platelet dysfunction and underlying 
coagulation disorders. Despite much speculation, 
contradictory evidence is also present, negating that 
hypobaric hypoxia, such that is experienced at a HA is 
involved in increased thrombosis [3]. CVT may be 
associated with poor outcome depending on the timely 
nature of diagnosis and treatment and the extent of the 
thrombosis. Bilateral or extensive thrombosis coupled 
with underlying coagulation disorder is associated with 
poor prognosis. Understanding the pathophysiology and 
the risk factors can help prevent incidence of CVT at 
high altitude as well as educate physicians and 
climbers about prompt diagnosis, treatment, screening 
and appropriate preventive measures. 
SEARCH METHODOLOGY
Comprehensive literature search was done on search 
engines PubMed and Google Scholar using the 
keywords “Cerebral Venous Thrombosis”, “High 
Altitude” and “Venous Thrombosis”. The following 
search query was used in PubMed: (“Cerebral Venous 
Thrombosis” [MeSh]) OR (Cerebral Venous 
Thrombosis[Title] AND High Altitude[Title]) OR (Cerebral 
Venous Thrombosis[Title] OR High Altitude) OR 
(Cerebral Venous Thrombosis at High Altitude[Title]). 
Inclusion criteria consisted of articles from journals that 
were PubMed indexed and published in the last 20 
years. A total of 40 articles were reviewed, out of which 
32 were included in the final paper. The references in 
papers found to be eligible were taken into account and 
screened for relevant information. The full text of all 
acceptable papers was accessed and read thoroughly. 
A comprehensive table of all pertinent information was 
made for easy access during article writing. Literature 
related to pathophysiology of venous thrombosis due to 
hypoxia was selected according to its relevance and 
recentness.
HIGH ALTITUDE (HA)
Barometric pressure decreases at an exponential rate 
as higher altitudes are reached, leading to a decrease 
in the partial pressure of Oxygen, which results in brain 
receiving less oxygen, hence inducing hypoxia [4]. CVT 
has been mostly described to occur between altitudes 
ranging from 2500m to 5500m [1]. It has been 
proposed that activation of coagulation factors leading 
to a prothrombotic state is rate dependent, i.e the 
more rapid the ascent to HA, higher the risk of 
developing CVT [5, 10].  Comparatively, gradual ascent 
to HA and well-acclimatized individuals pose a lesser 
risk of thrombosis. A study held in India compared 
1692 patient profiles comparing incidence of 
thrombosis in extremely HA (>5000m) and sea levels 
found that there was a 30 times higher incidence of 
CVT at HA [8]. Similarly, a study done on healthy, young 
soldiers at 3500m found a 30 times higher incidence 
of thrombosis [5].  Another study found that lowlanders 
posted at 3883m had 30-44 times increased 
incidence of deep vein thrombosis [6]. It was suggested 
that acute exposure to hypoxia solely cannot 
predispose to thrombosis without significant underlying 
shift in hemostasis [11]. There is a lack of good studies 
to determine the exact cause of hypercoagulability in 
HA especially since most of current studies in the West 
are performed in artificially simulated hypoxic 
environment. CVT can occur in lower than average 
altitude in people with pre-existing underlying 
prothrombotic state. Prolonged duration of stay is also 
associated with higher incidence of CVT as illustrated 
by various case reports. Table 1 shows incidents of CVT 
in high altitude.
TABLE 1: CASE REPORTS AND STUDIES WITH 
ASSOCIATED ALTITUDES AT WHICH CVT INCIDENCE 
OCCURRED.
AGE
At HA, CVT is typically observed in young to middle aged 
individuals [1]. Extremes of ages have also been 
reported with a 75-year-old man with an underlying 
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case of hyperhomocysteinemia developing deep CVT at 
an altitude of 2200 m for 3 days [12] and a 
19-year-old female developing sinus vein thrombosis 
after a high altitude training of 2 months [10]. 
GENDER
There’s an evident gender disparity in the 
documentation of CVT at high altitude, with a 
significantly higher incidence of CVT in males [1]. Most 
of the stronger studies were done on stationed soldiers 
and male trekkers [2,3,5,6,7,8]. and majority of the 
case reports document male patients [11, 
12,15,16,17,18,19]. Mountaineering is a 
male-dominated sport [14]. Women have additional 
risk factors such as oral contraceptive pills and 
pregnancy that predisposes them to venous 
thrombosis. Reported cases of females developing CVT 
at HA always had an existing underlying risk factor. A 
young female developing sinus vein thrombosis at HA 
had a history of oral contraceptive use that she claimed 
to have stopped taken 3 years prior to the incident 
[10]. Similarly, Shrestha et al. reported another female 
with heterozygous mutation of Factor V Leiden and low 
plasma levels of protein S suffered from CVT at 5600m 
[13]. A 39-year-old female was reported to develop 
bilateral deep subcortical infarction in combination with 
Acute Mountain Sickness [9].
CONGENITAL THROMBOPHILIAS
A pre-existing prothrombotic state, such as congenital 
thrombophilias, appears to the most common risk 
factor for developing CVT in a HA setting. A systemic 
review showed 9 out of 14 reported cases had an 
underlying hypercoagulable state with secondary 
polycythemia and Factor V Leiden mutations being the 
most common [1]. Heterozygous Factor V Leiden 
mutation increases the risk of thromboembolism by 
seven fold, whereas homozygous mutation increases 
the risk by eight-fold [20]. Bolous et al reported a case 
of sudden onset of right sided hemiplegia and aphasia 
secondary to CVT at 3000m in a 42-year-old man with 
congenital protein C deficiency, while Nair et al shares 
a case of a patient with a Protein S levels of 36% 
(normally 70-123%) presenting with CVT coupled with 
DVT. Both cases were distinct for positive family history 
of hypercoagulability [17]. Grabe et al recorded a case 
of homonymous hemaniopia from deep CVT leading to 
infarction of the optic tract and lateral geniculate 
nucleus at 4800m with an underlying heterozygous 
Factor V Leiden mutation and elevated Factor VIII levels 
[18]. Nair et al reports a case of 35-year-old patient 
with both intra-arterial and venous thrombosis at 
multiple sites including the superior sagittal sinus with 
an increased Plasminogen Activator Inhibitor 1 (PAI-1) 
due to 4G/4G genotype polymorphism [7].  Hassan et 
al brings to attention a case of a rare association 
between protein S deficiency and 
hyperhomocysteinemia that resulted in severe deep 
CVT [12]. 
OTHER RISK FACTORS
Factors that predispose to CVT formation include 
infections, head trauma, malignancy and drugs with 
prothrombotic tendencies. On HA, additional risk 
factors to consider are dehydration, immobility, 
polycythemia and changes in hemostasis. Dehydration 
secondary to reduced water intake, increased physical 
exertion as well as vomiting and diarrhea due to AMS 
can predispose to increased hemoconcentration 
[9,13]. Hemoconcentration also increases due to 
eventual acclimatization which leads to polycythemia 
and increased blood viscosity. The process of 
acclimatization brings about numerous changes in 
blood physiology leading to a higher risk of thrombus 
formation. Whilst full acclimatization is achieved, 
hematocrit is believed to have increased by 50% [20]. 
Significant increase in hemoglobin levels, hematocrit 
and RBC count is reported in various studies done on 
HA [5, 6]. Increased blood viscosity increases mean 
PTT and causes endothelial damage leading to clot 
formation. Polycythemia also results in increased 
cerebral blood flow, subsequently increasing 
intracranial pressure which in turn disrupts the cerebral 
venous blood flow. Although most cases of CVT at HA 
are observed in lowlanders acutely exposed to high 
altitude conditions, a few cases have also been 
observed in well acclimatized individuals native to such 
conditions. A case of vein of Galen thrombosis was 
observed in a permanent citizen of the Tibetan plateau 
(4000m) with an additional risk factor of recent history 
of trauma (bilateral acetabular fracture), high blood 
pressure, history of smoking and hemoglobin of 191 
g/L [16]. Similar case of a well acclimatized man 
presenting with occlusion of superior sagittal and right 
transverse sinuses around his 45th day at 5000m 
altitude, with an additional risk factor of pre-existing 
brain sinus narrowing and anomalies [19]. 10%-30% of 
the population is believed to have structural brain sinus 
anomalies. Extreme cold can trigger coagulation 
cascade [23].
SUGGESTED MECHANISMS
The precise etiopathology of thrombosis at HA is 
obscure. The literature contains conflicting studies 
offering a wide array of plausible explanations regarding 
the underlying mechanisms that lead to a 
hypercoaguable state at HA. Hypoxia-induced 
customization of hemostasis and coagulation factors 
results in simultaneous changes in multiple 
components of blood, predisposing to thrombosis. 
ROLE OF INFLAMMATION
Gupta et al emphasized the presence of an active 
proinflammatory response to hypoxia employing innate 
and adaptive immune cells resulting in aggravated 
venous thrombosis. This proinflammatory state 
develops in response to HA due to the action of 
Hypoxia-induced factor 1-alpha (HIF-1a) on NLRP3 
gene expression leading to formation of NLRP3 
inflammasome [21]. This study documents the 
presence of NLRP3, caspase-1 and IL- β in individuals 
who formed venous thrombosis. Additionally, another 
contributing factor is believed to be 
endothelin-1-mediated and interleukin-6-mediated 
endothelial activation and related inflammatory 
response [15].  
  
ROLE OF FACTOR VIII, PAI-1 
AND PLATELET ACTIVITY
Kicken et al attributed the increase in thrombin levels 
mediated by increased Factor VIII levels to be the cause 
of increased hypercoagulability at HA. Factor VIII levels 
were presumed to be increased due to the oxidative 
stress in circulation due to tissue hypoxia, asserting 
that hypoxia alters the “redox status” of the blood [6]. 
This study also found that platelet aggregation was 
reduced at HA, attributing to increased ADP and 
epinephrine. Antithrombin levels, D-dimers and 
coagulation factors remained unchanged as compared 
to sea levels. Interestingly, subjects which were 
pretreated with Vitamin E had a reduced incidence of 
venous thrombosis [6]. On the other hand, Kotwal et al 
studied the effect of high altitude on hemostasis at 
induction, 3 months and 8 months and reported a 
significant rise in platelet count and platelet activation 
factors (BTG and PF4). This study also reported a 
significant rise in hemoglobin, PAI-1 activity and plasma 
fibrinogen, asserting a positive relationship between 
the latter two and postulating the significance of PAI-1 
in “tilting the balance” towards thrombosis by 
decreasing fibrinolytic activity. Kotwal et al also 
emphasized that platelet aggregation in the context of 
thrombosis was not a reliable method, instead BTG and 
PF4 measured on ELISA assay were more illustrative of 
platelet activity [5]. 
Martin et al contradicts aforementioned findings by 
analyzing the kinetics of clot formation using 
thromboelastography to study the effects of hypoxia at 
4250 m and 5300m on coagulation [3].  It was found 
that exposure to hypoxia decreases blood coagulability 
[3].
ROLE OF INCREASED SYMPATHETIC ACTIVITY
Hypoxia is also believed to trigger the body’s 
sympathetic response and increased sympathetic 
activity has a strong relationship with stroke [20, 22]. 
Constantly increased norepinephrine activates platelet 
hyperfunctioning leading to a hypercoagulable state 
[22]. 
Clinical Features and Diagnostic Challenges
There’s a considerable variation in the clinical features 
associated with CVT. Severity of the presentation is 
contingent with the extent of the thrombosis, sinuses 
involved and development of venous collaterals [12]. 
Most common signs and symptoms include 
headaches, focal neurological deficits, seizures and 
altered mental status [1, 2]. Other symptoms include 
papilledema and behavioral changes. Both cytotoxic 
and vasogenic cerebral edema are associated with CVT 
[28]. These present with an acute onset and the 
headaches are often associated with vomiting, 
confusion and loss of consciousness. Deep CVT 
involving the thalamus, basal ganglia and subcortical 
white matter presents as serious neurological 
emergency [12,16,18]. 
More common neurological conditions associated with 
high altitude are High-altitude headache (HAH), Acute 
mountain sickness (AMS) and High altitude cerebral 
edema (HACE). These render the accurate diagnosis 
difficult due to several overlapping clinical features. For 
example, HACE presents as altered mental status, 
ataxia of gait, and psychiatric changes that can lead to 
deep coma. Table 2 illustrates the clinical features of 
patients who developed CVT at HA. 
anticoagulation and rehabilitation [29]. Failure to 
anticoagulated results in poor prognosis [9, 29]. 25% 
of patients with CVT deteriorate despite adequate 
anticoagulation [2]. Overall mortality rate associated 
with CVT is 34.2% [29]. Bilateral CVT (which male up 
3%-8% of all CVT) and deep CVT present with severe 
clinical features and are associated with poor clinical 
outcome [2,9,16,18]. According to the International 
Study of Cerebral Vein and Dural Thrombosis (ISCVT) 
13% had poor neurological outcome whereas 4.3% 
were recorded to have died during the acute phase. 
Bushnaq et al demonstrated that the most significant 
predictor of poor prognosis to be altered or decreased 
mental status. Other indicators for poor prognosis are 
seizures, papilledema, hyponatremia (<139mEq/L), 
low platelet count (<225x109/L) and involvement of 
more than one sinus [2]. Endovascular therapy has 
been used as a salvage intervention, however there’s 
not much evidence to support its efficiency in 
decreasing mortality. Delaying thrombectomy can result 
in fibrosing of the thrombus leading to permanent 
neurological damage [2].
TREATMENT
 
Treatment of choice for CVT at HA is anticoagulation 
with subcutaneous Low Molecular Weight Heparin [32]. 
In the acute phase of the disease, first concern should 
be to stabilize and prevent cerebral herniation [28]. 
Decompressive surgery is strongly suggested for acute 
CVT with parenchymal involvement [32]. Use of 
acetazolamide, steroids and thrombolysis in acute CVT 
is discouraged [32]. For medically-refractory cases, 
mechanical thrombectomy can be considered [31]. 
Long term anticoagulation with warfarin or newer oral 
anticoagulants (NOACs) may be required for variable 
periods.
PROPHYLAXIS
LMWH and Warfarin are proven to be acceptable 
prophylaxis against hypercoagulabity at HA.  Use of oral 
anticoagulants after an episode of CVT to prevent 
further incidence has low evidence of impact and not 
recommended [32].
Oral Contraceptive Pills should be discontinued by 
females before embarking on a HA journey.
FUTURE DIRECTIONS
The exact incidence and mortality rate of CVT on a HA 
is unknown. Almost all epidemiological studies about 
CVT are based on normal altitude, not taking in account 
the additional risk factors associated with hypobaric 
hypoxia. Most high altitude studies were done on male, 
middle-aged soldiers or mountaineers without proper 
controls, this gives rise to bias and inaccuracy. 
Multi-center academic collaborations between 
institutions investigating incidence of high 
altitude-associated CVT can help improve the current 
understanding about involved risk factors. A case 
control study will be useful in identifying risk factors for 
high altitude CVT. Future intervention trials could be 
planned targeting high risk populations. Determining 
the precise altitude at which the risk of developing CVT 
increases significantly can help caution susceptible 
individuals. Although screening for thrombophilias is 
not recommended for CVT at normal altitude [32], 
studies showing a strong relationship between the two 
should prompt further research on whether 
thrombophilia screening should be incorporated in the 
diagnostic protocol for CVT cases presenting at a HA 
setting. Those set to experience hypobaric hypoxic 
conditions should also get routine blood counts to 
screen for polycythemia and thrombocytosis. Screening 
for Vitamin B12 and Folate levels can help detect a 
state of hyperhomocysteinemia. Health care 
professionals should also be trained to consider and 
diagnose CVT in patients with neurological symptoms. 
Availability of imaging modalities such as CT and MRI 
scan can lead to quicker diagnosis and treatment. More 
research should be focused on the underlying 
pathophysiology and mechanisms involved with 
hypoxia-associated CVT to create effective prophylaxis, 
protocols and treatment plans.
CONCLUSION
 
Cerebral Venous Thrombosis occurring at high altitude 
is a neurological emergency that requires timely 
diagnosis and treatment. It has complex underlying 
mechanisms and etiologies as well as numerous 
clinical presentations.  Understanding the predisposing 
factors to this phenomenon can lead to effective 
preventive measures, quicker diagnosis and 
management. Individuals with history of coagulation 
abnormalities should be screened for underlying 
thrombophilias and cautiously ascend to higher 
altitudes. CVT should be considered in all neurological 
clinical presentations at high altitude. High altitude 
trekkers should be educated on how to keep hydrated 
and avoid immobility, exposure to extreme cold and 
seeking immediate help for symptoms like headache 
and disturbed mental status. Patients with no 
contraindications to anticoagulation should be 
immediately anticoagulated with appropriate drugs.
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DIAGNOSIS
Neuroimaging plays a vital role in the diagnosis and 
clinical outcome [31]. Two most common imaging 
modalities used to confirm diagnosis of CVT are CT scan 
and MRI, and MRV when not visualized in MRI [1, 32]. 
There are alterations in the intensity of the thrombus 
depending on its age [31]. Most common sinuses to be 
affected is the superior sagittal sinus and transverse 
sinus [1, 2]. Kim et al weren’t able to locate any 
indication of thrombosis except for vasogenic edema 
with a hemorrhagic component on MRI [15]. D-dimer 
level can be effective to diagnose restricted sinus 
involvement or in older individuals, however, there is a 
chance of false negative results and its role in diagnosis 
remains controversial [24, 32]. Imaging modality of 
choice to visualize deep CVT is MRI T1W1 [12]. Family 
history of coagulation disorders should raise suspicion 
for CVT for anyone presenting with neurological findings 
at HA. Nair et al demonstrated that PA1-1 
polymorphism lead to widespread thrombosis at 
multiple sites including aorta, bilateral iliac arteries, 
middle cerebral artery and CVT of superior sagittal sinus 
[7].
PROGNOSIS
 
The main determinant of prognosis is timely diagnosis 
and treatment. Hemorrhage is a common sequela of 
CVT and worsens clinical outcome [11]. Most cases of 
CVT show good recovery with a combination of quick 
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nature of diagnosis and treatment and the extent of the 
thrombosis. Bilateral or extensive thrombosis coupled 
with underlying coagulation disorder is associated with 
poor prognosis. Understanding the pathophysiology and 
the risk factors can help prevent incidence of CVT at 
high altitude as well as educate physicians and 
climbers about prompt diagnosis, treatment, screening 
and appropriate preventive measures. 
SEARCH METHODOLOGY
Comprehensive literature search was done on search 
engines PubMed and Google Scholar using the 
keywords “Cerebral Venous Thrombosis”, “High 
Altitude” and “Venous Thrombosis”. The following 
search query was used in PubMed: (“Cerebral Venous 
Thrombosis” [MeSh]) OR (Cerebral Venous 
Thrombosis[Title] AND High Altitude[Title]) OR (Cerebral 
Venous Thrombosis[Title] OR High Altitude) OR 
(Cerebral Venous Thrombosis at High Altitude[Title]). 
Inclusion criteria consisted of articles from journals that 
were PubMed indexed and published in the last 20 
years. A total of 40 articles were reviewed, out of which 
32 were included in the final paper. The references in 
papers found to be eligible were taken into account and 
screened for relevant information. The full text of all 
acceptable papers was accessed and read thoroughly. 
A comprehensive table of all pertinent information was 
made for easy access during article writing. Literature 
related to pathophysiology of venous thrombosis due to 
hypoxia was selected according to its relevance and 
recentness.
HIGH ALTITUDE (HA)
Barometric pressure decreases at an exponential rate 
as higher altitudes are reached, leading to a decrease 
in the partial pressure of Oxygen, which results in brain 
receiving less oxygen, hence inducing hypoxia [4]. CVT 
has been mostly described to occur between altitudes 
ranging from 2500m to 5500m [1]. It has been 
proposed that activation of coagulation factors leading 
to a prothrombotic state is rate dependent, i.e the 
more rapid the ascent to HA, higher the risk of 
developing CVT [5, 10].  Comparatively, gradual ascent 
to HA and well-acclimatized individuals pose a lesser 
risk of thrombosis. A study held in India compared 
1692 patient profiles comparing incidence of 
thrombosis in extremely HA (>5000m) and sea levels 
found that there was a 30 times higher incidence of 
CVT at HA [8]. Similarly, a study done on healthy, young 
soldiers at 3500m found a 30 times higher incidence 
of thrombosis [5].  Another study found that lowlanders 
posted at 3883m had 30-44 times increased 
incidence of deep vein thrombosis [6]. It was suggested 
that acute exposure to hypoxia solely cannot 
predispose to thrombosis without significant underlying 
shift in hemostasis [11]. There is a lack of good studies 
to determine the exact cause of hypercoagulability in 
HA especially since most of current studies in the West 
are performed in artificially simulated hypoxic 
environment. CVT can occur in lower than average 
altitude in people with pre-existing underlying 
prothrombotic state. Prolonged duration of stay is also 
associated with higher incidence of CVT as illustrated 
by various case reports. Table 1 shows incidents of CVT 
in high altitude.
TABLE 1: CASE REPORTS AND STUDIES WITH 
ASSOCIATED ALTITUDES AT WHICH CVT INCIDENCE 
OCCURRED.
AGE
At HA, CVT is typically observed in young to middle aged 
individuals [1]. Extremes of ages have also been 
reported with a 75-year-old man with an underlying 
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case of hyperhomocysteinemia developing deep CVT at 
an altitude of 2200 m for 3 days [12] and a 
19-year-old female developing sinus vein thrombosis 
after a high altitude training of 2 months [10]. 
GENDER
There’s an evident gender disparity in the 
documentation of CVT at high altitude, with a 
significantly higher incidence of CVT in males [1]. Most 
of the stronger studies were done on stationed soldiers 
and male trekkers [2,3,5,6,7,8]. and majority of the 
case reports document male patients [11, 
12,15,16,17,18,19]. Mountaineering is a 
male-dominated sport [14]. Women have additional 
risk factors such as oral contraceptive pills and 
pregnancy that predisposes them to venous 
thrombosis. Reported cases of females developing CVT 
at HA always had an existing underlying risk factor. A 
young female developing sinus vein thrombosis at HA 
had a history of oral contraceptive use that she claimed 
to have stopped taken 3 years prior to the incident 
[10]. Similarly, Shrestha et al. reported another female 
with heterozygous mutation of Factor V Leiden and low 
plasma levels of protein S suffered from CVT at 5600m 
[13]. A 39-year-old female was reported to develop 
bilateral deep subcortical infarction in combination with 
Acute Mountain Sickness [9].
CONGENITAL THROMBOPHILIAS
A pre-existing prothrombotic state, such as congenital 
thrombophilias, appears to the most common risk 
factor for developing CVT in a HA setting. A systemic 
review showed 9 out of 14 reported cases had an 
underlying hypercoagulable state with secondary 
polycythemia and Factor V Leiden mutations being the 
most common [1]. Heterozygous Factor V Leiden 
mutation increases the risk of thromboembolism by 
seven fold, whereas homozygous mutation increases 
the risk by eight-fold [20]. Bolous et al reported a case 
of sudden onset of right sided hemiplegia and aphasia 
secondary to CVT at 3000m in a 42-year-old man with 
congenital protein C deficiency, while Nair et al shares 
a case of a patient with a Protein S levels of 36% 
(normally 70-123%) presenting with CVT coupled with 
DVT. Both cases were distinct for positive family history 
of hypercoagulability [17]. Grabe et al recorded a case 
of homonymous hemaniopia from deep CVT leading to 
infarction of the optic tract and lateral geniculate 
nucleus at 4800m with an underlying heterozygous 
Factor V Leiden mutation and elevated Factor VIII levels 
[18]. Nair et al reports a case of 35-year-old patient 
with both intra-arterial and venous thrombosis at 
multiple sites including the superior sagittal sinus with 
an increased Plasminogen Activator Inhibitor 1 (PAI-1) 
due to 4G/4G genotype polymorphism [7].  Hassan et 
al brings to attention a case of a rare association 
between protein S deficiency and 
hyperhomocysteinemia that resulted in severe deep 
CVT [12]. 
OTHER RISK FACTORS
Factors that predispose to CVT formation include 
infections, head trauma, malignancy and drugs with 
prothrombotic tendencies. On HA, additional risk 
factors to consider are dehydration, immobility, 
polycythemia and changes in hemostasis. Dehydration 
secondary to reduced water intake, increased physical 
exertion as well as vomiting and diarrhea due to AMS 
can predispose to increased hemoconcentration 
[9,13]. Hemoconcentration also increases due to 
eventual acclimatization which leads to polycythemia 
and increased blood viscosity. The process of 
acclimatization brings about numerous changes in 
blood physiology leading to a higher risk of thrombus 
formation. Whilst full acclimatization is achieved, 
hematocrit is believed to have increased by 50% [20]. 
Significant increase in hemoglobin levels, hematocrit 
and RBC count is reported in various studies done on 
HA [5, 6]. Increased blood viscosity increases mean 
PTT and causes endothelial damage leading to clot 
formation. Polycythemia also results in increased 
cerebral blood flow, subsequently increasing 
intracranial pressure which in turn disrupts the cerebral 
venous blood flow. Although most cases of CVT at HA 
are observed in lowlanders acutely exposed to high 
altitude conditions, a few cases have also been 
observed in well acclimatized individuals native to such 
conditions. A case of vein of Galen thrombosis was 
observed in a permanent citizen of the Tibetan plateau 
(4000m) with an additional risk factor of recent history 
of trauma (bilateral acetabular fracture), high blood 
pressure, history of smoking and hemoglobin of 191 
g/L [16]. Similar case of a well acclimatized man 
presenting with occlusion of superior sagittal and right 
transverse sinuses around his 45th day at 5000m 
altitude, with an additional risk factor of pre-existing 
brain sinus narrowing and anomalies [19]. 10%-30% of 
the population is believed to have structural brain sinus 
anomalies. Extreme cold can trigger coagulation 
cascade [23].
SUGGESTED MECHANISMS
The precise etiopathology of thrombosis at HA is 
obscure. The literature contains conflicting studies 
offering a wide array of plausible explanations regarding 
the underlying mechanisms that lead to a 
hypercoaguable state at HA. Hypoxia-induced 
customization of hemostasis and coagulation factors 
results in simultaneous changes in multiple 
components of blood, predisposing to thrombosis. 
ROLE OF INFLAMMATION
Gupta et al emphasized the presence of an active 
proinflammatory response to hypoxia employing innate 
and adaptive immune cells resulting in aggravated 
venous thrombosis. This proinflammatory state 
develops in response to HA due to the action of 
Hypoxia-induced factor 1-alpha (HIF-1a) on NLRP3 
gene expression leading to formation of NLRP3 
inflammasome [21]. This study documents the 
presence of NLRP3, caspase-1 and IL- β in individuals 
who formed venous thrombosis. Additionally, another 
contributing factor is believed to be 
endothelin-1-mediated and interleukin-6-mediated 
endothelial activation and related inflammatory 
response [15].  
  
ROLE OF FACTOR VIII, PAI-1 
AND PLATELET ACTIVITY
Kicken et al attributed the increase in thrombin levels 
mediated by increased Factor VIII levels to be the cause 
of increased hypercoagulability at HA. Factor VIII levels 
were presumed to be increased due to the oxidative 
stress in circulation due to tissue hypoxia, asserting 
that hypoxia alters the “redox status” of the blood [6]. 
This study also found that platelet aggregation was 
reduced at HA, attributing to increased ADP and 
epinephrine. Antithrombin levels, D-dimers and 
coagulation factors remained unchanged as compared 
to sea levels. Interestingly, subjects which were 
pretreated with Vitamin E had a reduced incidence of 
venous thrombosis [6]. On the other hand, Kotwal et al 
studied the effect of high altitude on hemostasis at 
induction, 3 months and 8 months and reported a 
significant rise in platelet count and platelet activation 
factors (BTG and PF4). This study also reported a 
significant rise in hemoglobin, PAI-1 activity and plasma 
fibrinogen, asserting a positive relationship between 
the latter two and postulating the significance of PAI-1 
in “tilting the balance” towards thrombosis by 
decreasing fibrinolytic activity. Kotwal et al also 
emphasized that platelet aggregation in the context of 
thrombosis was not a reliable method, instead BTG and 
PF4 measured on ELISA assay were more illustrative of 
platelet activity [5]. 
Martin et al contradicts aforementioned findings by 
analyzing the kinetics of clot formation using 
thromboelastography to study the effects of hypoxia at 
4250 m and 5300m on coagulation [3].  It was found 
that exposure to hypoxia decreases blood coagulability 
[3].
ROLE OF INCREASED SYMPATHETIC ACTIVITY
Hypoxia is also believed to trigger the body’s 
sympathetic response and increased sympathetic 
activity has a strong relationship with stroke [20, 22]. 
Constantly increased norepinephrine activates platelet 
hyperfunctioning leading to a hypercoagulable state 
[22]. 
Clinical Features and Diagnostic Challenges
There’s a considerable variation in the clinical features 
associated with CVT. Severity of the presentation is 
contingent with the extent of the thrombosis, sinuses 
involved and development of venous collaterals [12]. 
Most common signs and symptoms include 
headaches, focal neurological deficits, seizures and 
altered mental status [1, 2]. Other symptoms include 
papilledema and behavioral changes. Both cytotoxic 
and vasogenic cerebral edema are associated with CVT 
[28]. These present with an acute onset and the 
headaches are often associated with vomiting, 
confusion and loss of consciousness. Deep CVT 
involving the thalamus, basal ganglia and subcortical 
white matter presents as serious neurological 
emergency [12,16,18]. 
More common neurological conditions associated with 
high altitude are High-altitude headache (HAH), Acute 
mountain sickness (AMS) and High altitude cerebral 
edema (HACE). These render the accurate diagnosis 
difficult due to several overlapping clinical features. For 
example, HACE presents as altered mental status, 
ataxia of gait, and psychiatric changes that can lead to 
deep coma. Table 2 illustrates the clinical features of 
patients who developed CVT at HA. 
 
anticoagulation and rehabilitation [29]. Failure to 
anticoagulated results in poor prognosis [9, 29]. 25% 
of patients with CVT deteriorate despite adequate 
anticoagulation [2]. Overall mortality rate associated 
with CVT is 34.2% [29]. Bilateral CVT (which male up 
3%-8% of all CVT) and deep CVT present with severe 
clinical features and are associated with poor clinical 
outcome [2,9,16,18]. According to the International 
Study of Cerebral Vein and Dural Thrombosis (ISCVT) 
13% had poor neurological outcome whereas 4.3% 
were recorded to have died during the acute phase. 
Bushnaq et al demonstrated that the most significant 
predictor of poor prognosis to be altered or decreased 
mental status. Other indicators for poor prognosis are 
seizures, papilledema, hyponatremia (<139mEq/L), 
low platelet count (<225x109/L) and involvement of 
more than one sinus [2]. Endovascular therapy has 
been used as a salvage intervention, however there’s 
not much evidence to support its efficiency in 
decreasing mortality. Delaying thrombectomy can result 
in fibrosing of the thrombus leading to permanent 
neurological damage [2].
TREATMENT
 
Treatment of choice for CVT at HA is anticoagulation 
with subcutaneous Low Molecular Weight Heparin [32]. 
In the acute phase of the disease, first concern should 
be to stabilize and prevent cerebral herniation [28]. 
Decompressive surgery is strongly suggested for acute 
CVT with parenchymal involvement [32]. Use of 
acetazolamide, steroids and thrombolysis in acute CVT 
is discouraged [32]. For medically-refractory cases, 
mechanical thrombectomy can be considered [31]. 
Long term anticoagulation with warfarin or newer oral 
anticoagulants (NOACs) may be required for variable 
periods.
PROPHYLAXIS
LMWH and Warfarin are proven to be acceptable 
prophylaxis against hypercoagulabity at HA.  Use of oral 
anticoagulants after an episode of CVT to prevent 
further incidence has low evidence of impact and not 
recommended [32].
Oral Contraceptive Pills should be discontinued by 
females before embarking on a HA journey.
FUTURE DIRECTIONS
The exact incidence and mortality rate of CVT on a HA 
is unknown. Almost all epidemiological studies about 
CVT are based on normal altitude, not taking in account 
the additional risk factors associated with hypobaric 
hypoxia. Most high altitude studies were done on male, 
middle-aged soldiers or mountaineers without proper 
controls, this gives rise to bias and inaccuracy. 
Multi-center academic collaborations between 
institutions investigating incidence of high 
altitude-associated CVT can help improve the current 
understanding about involved risk factors. A case 
control study will be useful in identifying risk factors for 
high altitude CVT. Future intervention trials could be 
planned targeting high risk populations. Determining 
the precise altitude at which the risk of developing CVT 
increases significantly can help caution susceptible 
individuals. Although screening for thrombophilias is 
not recommended for CVT at normal altitude [32], 
studies showing a strong relationship between the two 
should prompt further research on whether 
thrombophilia screening should be incorporated in the 
diagnostic protocol for CVT cases presenting at a HA 
setting. Those set to experience hypobaric hypoxic 
conditions should also get routine blood counts to 
screen for polycythemia and thrombocytosis. Screening 
for Vitamin B12 and Folate levels can help detect a 
state of hyperhomocysteinemia. Health care 
professionals should also be trained to consider and 
diagnose CVT in patients with neurological symptoms. 
Availability of imaging modalities such as CT and MRI 
scan can lead to quicker diagnosis and treatment. More 
research should be focused on the underlying 
pathophysiology and mechanisms involved with 
hypoxia-associated CVT to create effective prophylaxis, 
protocols and treatment plans.
CONCLUSION
 
Cerebral Venous Thrombosis occurring at high altitude 
is a neurological emergency that requires timely 
diagnosis and treatment. It has complex underlying 
mechanisms and etiologies as well as numerous 
clinical presentations.  Understanding the predisposing 
factors to this phenomenon can lead to effective 
preventive measures, quicker diagnosis and 
management. Individuals with history of coagulation 
abnormalities should be screened for underlying 
thrombophilias and cautiously ascend to higher 
altitudes. CVT should be considered in all neurological 
clinical presentations at high altitude. High altitude 
trekkers should be educated on how to keep hydrated 
and avoid immobility, exposure to extreme cold and 
seeking immediate help for symptoms like headache 
and disturbed mental status. Patients with no 
contraindications to anticoagulation should be 
immediately anticoagulated with appropriate drugs.
References
1. Zavanone C, Panebianco M, Yger M, Borden A, 
Restivo D, Angelini C, Pavone A, Grimod G, Rosso 
C, Dupont S. Cerebral venous thrombosis at high 
altitude: a systematic review. Revue neurologique. 
2017 Apr 1;173(4):189-93.
2. Bushnaq SA, Qeadan F, Thacker T, Abbas M, 
Carlson AP. High-Risk Features of Delayed Clinical 
Progression in Cerebral Venous Thrombosis: A 
Proposed Prediction Score for Early Intervention. 
Interventional Neurology. 2018;7(6):297-307.
3. Martin DS, Pate JS, Vercueil A, Doyle PW, Mythen 
MG, Grocott MP, Caudwell Xtreme Everest 
Research Group. Reduced coagulation at high 
altitude identified by thromboelastography. 
Thrombosis and haemostasis. 2012 Jun 
1;107(6):1066.
4. Wilson MH, Newman S, Imray CH. The cerebral 
effects of ascent to high altitudes. The Lancet 
Neurology. 2009 Feb 1;8(2):175-91.
5. Kotwal J, Apte CV, Kotwal A, Mukherjee B, Jayaram 
J. High altitude: a hypercoagulable state: results of 
a prospective cohort study. Thrombosis research. 
2007 Jan 1;120(3):391-7.
6. Kicken CH, Ninivaggi M, Konings J, Moorlag M, 
Huskens D, Remijn JA, Bloemen S, Lancé MD, De 
Laat B. Hypobaric Hypoxia Causes Elevated 
Thrombin Generation Mediated by FVIII that is 
Balanced by Decreased Platelet Activation. 
Thrombosis and haemostasis. 2018 
May;118(05):883-92.
7. Nair V, Yanamandra U, Kumud R, Ghosh K. PAI-1 
polymorphism as a cause of severe high altitude 
associated arteriovenous thrombosis. BMJ case 
reports. 2016 Nov 23;2016.
8. Anand AC, Jha SK, Saha A, Sharma V, Adya CM. 
Thrombosis as a complication of extended stay at 
high altitude. National Medical Journal of India. 
2001 Jan 1;14(4):197-201.
9. Cheng S, Chng SM, Singh R. Cerebral venous 
infarction during a high altitude expedition. 
Singapore Med J. 2009 Aug 1;50(8):e306-8.
10. Torgovicky R, Azaria B, Grossman A, Eliyahu U, 
Goldstein L. Sinus vein thrombosis following 
exposure to simulated high altitude. Aviation, 
space, and environmental medicine. 2005 Feb 
1;76(2):144-6.
11. Boulos P, Kouroukis C, Blake G. Superior sagittal 
sinus thrombosis occurring at high altitude 
associated with protein C deficiency. Acta 
haematologica. 1999;102(2):104-6.
12. Hassan KM, Kumar D. Reversible diencephalic 
dysfunction as presentation of deep cerebral 
venous thrombosis due to hyperhomocysteinemia 
and protein S deficiency: Documentation of a 
case. Journal of neurosciences in rural practice. 
2013 Apr;4(2):193.
13. Shrestha P, Basnyat B, Küpper T, van der Giet S. 
Cerebral venous sinus thrombosis at high altitude. 
High altitude medicine & biology. 2012 Mar 
1;13(1):60-2.
14. 
https://www.nytimes.com/2010/05/23/sports/23g
uides.html
15. Kim JH, Kim SJ, Kim HY. Right Hand Weakness 
and Headache During Ascent to Mount Everest: A 
Case of Cerebral Venous Infarction. The 
neurologist. 2017 May 1;22(3):98-100.
16. Ye DP, Zhang SL, Xu QH, Wei LJ. A case of Galen 
vein thrombosis occurring after bilateral acetabular 
fractures in the Tibet plateau–what can we learn?. 
Chinese Journal of Traumatology. 2017 Oct 
1;20(5):308-10.
17. Nair V, Mohapatro AK, Sreedhar M, Indrajeet IK, 
Tewari AK, Anand AC, Mathew OP. A case of 
hereditary protein S deficiency presenting with 
cerebral sinus venous thrombosis and deep vein 
thrombosis at high altitude. Acta haematologica. 
2008;119(3):158-61.
18. Grabe HM, Bapuraj JR, Wesolowski JR, Parmar H, 
Trobe JD. Homonymous hemianopia from 
infarction of the optic tract and lateral geniculate 
nucleus in deep cerebral venous thrombosis. 
Journal of Neuro-Ophthalmology. 2012 Mar 
1;32(1):38-41.
19. Saito S, Tanaka SK. A case of cerebral sinus 
thrombosis developed during a high-altitude 
expedition to Gasherbrum I. Wilderness & 
environmental medicine. 2003 Dec 
1;14(4):226-30.
20. Segler CP. Prophylaxis of climbers for prevention of 
embolic accidents. Medical hypotheses. 2001 Oct 
1;57(4):472-5.
21. Gupta N, Sahu A, Prabhakar A, Chatterjee T, Tyagi 
T, Kumari B, Khan N, Nair V, Bajaj N, Sharma M, 
Ashraf MZ. Activation of NLRP3 inflammasome 
complex potentiates venous thrombosis in 
response to hypoxia. Proceedings of the National 
Academy of Sciences. 2017 May 
2;114(18):4763-8.
22. Preckel D, von Känel R. Regulation of hemostasis 
by the sympathetic nervous system: any 
contribution to coronary artery disease?. Heart 
Drug. 2004;4(3):123-30.
23. Polderman KH. Hypothermia and coagulation. 
InCritical Care 2012 Apr (Vol. 16, No. 2, p. A20). 
BioMed Central.
24. Hashami L, Rakhshan V, Karimian H, Moghaddasi 
M. Diagnostic Value of D-Dimer's Serum Level in 
Iranian Patients with Cerebral Venous Thrombosis. 
Neurology international. 2016 Jun;8(2):6310-.
25. Ferro JM, Canhão P, Stam J, Bousser MG, 
Barinagarrementeria F. Prognosis of cerebral vein 
and dural sinus thrombosis: results of the 
International Study on Cerebral Vein and Dural 
Sinus Thrombosis (ISCVT). Stroke. 2004 Mar 
1;35(3):664-70.
26. Song SY, Asaji T, Tanizaki Y, Fujimaki T, Matsutani 
M, Okeda R. Cerebral thrombosis at altitude: its 
pathogenesis and the problems of prevention and 
treatment. Aviation, space, and environmental 
medicine. 1986 Jan;57(1):71-6.
27. Skaiaa SC, Stave H. Recurrent sagittal sinus 
thrombosis occurring at high altitude during 
expeditions to Cho Oyu. Wilderness & 
environmental medicine. 2006 Jun 
1;17(2):132-6.
28. Stam J. Thrombosis of the cerebral veins and 
sinuses. New England Journal of Medicine. 2005 
Apr 28;352(17):1791-8.
29. Luo Y, Tian X, Wang X. Diagnosis and Treatment of 
Cerebral Venous Thrombosis: A Review. Frontiers 
in aging neuroscience. 2018 Jan 30;10:2.
30. Paliwal AK, Gupta M, Peeyush P, Sharma V. 
Imaging the diverse presentations of cerebral 
venous thrombosis occurring at high altitude area 
in Armed Forces personnel: Case series. Medical 
Journal Armed Forces India. 2018 May 28.
31. Dmytriw AA, Song JS, Yu E, Poon CS. Cerebral 
venous thrombosis: state of the art diagnosis and 
management. Neuroradiology. 2018 May 11:1-7.
32. Ferro JM, Bousser MG, Canhão P, Coutinho JM, 
Crassard I, Dentali F, di Minno M, Maino A, 
Martinelli I, Masuhr F, de Sousa DA. European 
Stroke Organization guideline for the diagnosis and 
treatment of cerebral venous 
thrombosis–endorsed by the European Academy of 
Neurology. European Stroke Journal. 2017 
Sep;2(3):195-221.
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level) 
Song et al26 – case series 
(1986) 
5200m 
Bolous et al11 – case report 
(1999) 
3000m 
Anand et al8 – case series 
(2001) 
3000m-5999m 
Saito et al19 – case report 
(2003) 
5000m 
Torgovicky et al10 – case 
report (2005) 
10,000m-13,000m 
Skaiaa and Stave27 – case 
report (2006) 
8201 m 
J. Kotwal et al5 - cohort 
study (2007) 
3500m 
Nair et al17 – case report 
(2008) 
4572m 
Cheng et al9 - case report 
(2009) 
4000m 
Grabe et al18 – case report 
(2012) 
4877m 
Shrestha et al13 – case 
report (2012) 
5600m 
Hassan et al12 – case report 
(2013) 
2200m 
Nair et al7 – case report 
(2016) 
6400m 
Te DP et al16 – case report 
(2017) 
4000m 
Kim et al15 – case report 
(2017) 
5970m 
A.K. Paliwal et al30 – case 
series (2018)_ 
3000m-3800m 
 
DIAGNOSIS
Neuroimaging plays a vital role in the diagnosis and 
clinical outcome [31]. Two most common imaging 
modalities used to confirm diagnosis of CVT are CT scan 
and MRI, and MRV when not visualized in MRI [1, 32]. 
There are alterations in the intensity of the thrombus 
depending on its age [31]. Most common sinuses to be 
affected is the superior sagittal sinus and transverse 
sinus [1, 2]. Kim et al weren’t able to locate any 
indication of thrombosis except for vasogenic edema 
with a hemorrhagic component on MRI [15]. D-dimer 
level can be effective to diagnose restricted sinus 
involvement or in older individuals, however, there is a 
chance of false negative results and its role in diagnosis 
remains controversial [24, 32]. Imaging modality of 
choice to visualize deep CVT is MRI T1W1 [12]. Family 
history of coagulation disorders should raise suspicion 
for CVT for anyone presenting with neurological findings 
at HA. Nair et al demonstrated that PA1-1 
polymorphism lead to widespread thrombosis at 
multiple sites including aorta, bilateral iliac arteries, 
middle cerebral artery and CVT of superior sagittal sinus 
[7].
PROGNOSIS
 
The main determinant of prognosis is timely diagnosis 
and treatment. Hemorrhage is a common sequela of 
CVT and worsens clinical outcome [11]. Most cases of 
CVT show good recovery with a combination of quick 
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nature of diagnosis and treatment and the extent of the 
thrombosis. Bilateral or extensive thrombosis coupled 
with underlying coagulation disorder is associated with 
poor prognosis. Understanding the pathophysiology and 
the risk factors can help prevent incidence of CVT at 
high altitude as well as educate physicians and 
climbers about prompt diagnosis, treatment, screening 
and appropriate preventive measures. 
SEARCH METHODOLOGY
Comprehensive literature search was done on search 
engines PubMed and Google Scholar using the 
keywords “Cerebral Venous Thrombosis”, “High 
Altitude” and “Venous Thrombosis”. The following 
search query was used in PubMed: (“Cerebral Venous 
Thrombosis” [MeSh]) OR (Cerebral Venous 
Thrombosis[Title] AND High Altitude[Title]) OR (Cerebral 
Venous Thrombosis[Title] OR High Altitude) OR 
(Cerebral Venous Thrombosis at High Altitude[Title]). 
Inclusion criteria consisted of articles from journals that 
were PubMed indexed and published in the last 20 
years. A total of 40 articles were reviewed, out of which 
32 were included in the final paper. The references in 
papers found to be eligible were taken into account and 
screened for relevant information. The full text of all 
acceptable papers was accessed and read thoroughly. 
A comprehensive table of all pertinent information was 
made for easy access during article writing. Literature 
related to pathophysiology of venous thrombosis due to 
hypoxia was selected according to its relevance and 
recentness.
HIGH ALTITUDE (HA)
Barometric pressure decreases at an exponential rate 
as higher altitudes are reached, leading to a decrease 
in the partial pressure of Oxygen, which results in brain 
receiving less oxygen, hence inducing hypoxia [4]. CVT 
has been mostly described to occur between altitudes 
ranging from 2500m to 5500m [1]. It has been 
proposed that activation of coagulation factors leading 
to a prothrombotic state is rate dependent, i.e the 
more rapid the ascent to HA, higher the risk of 
developing CVT [5, 10].  Comparatively, gradual ascent 
to HA and well-acclimatized individuals pose a lesser 
risk of thrombosis. A study held in India compared 
1692 patient profiles comparing incidence of 
thrombosis in extremely HA (>5000m) and sea levels 
found that there was a 30 times higher incidence of 
CVT at HA [8]. Similarly, a study done on healthy, young 
soldiers at 3500m found a 30 times higher incidence 
of thrombosis [5].  Another study found that lowlanders 
posted at 3883m had 30-44 times increased 
incidence of deep vein thrombosis [6]. It was suggested 
that acute exposure to hypoxia solely cannot 
predispose to thrombosis without significant underlying 
shift in hemostasis [11]. There is a lack of good studies 
to determine the exact cause of hypercoagulability in 
HA especially since most of current studies in the West 
are performed in artificially simulated hypoxic 
environment. CVT can occur in lower than average 
altitude in people with pre-existing underlying 
prothrombotic state. Prolonged duration of stay is also 
associated with higher incidence of CVT as illustrated 
by various case reports. Table 1 shows incidents of CVT 
in high altitude.
TABLE 1: CASE REPORTS AND STUDIES WITH 
ASSOCIATED ALTITUDES AT WHICH CVT INCIDENCE 
OCCURRED.
AGE
At HA, CVT is typically observed in young to middle aged 
individuals [1]. Extremes of ages have also been 
reported with a 75-year-old man with an underlying 
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case of hyperhomocysteinemia developing deep CVT at 
an altitude of 2200 m for 3 days [12] and a 
19-year-old female developing sinus vein thrombosis 
after a high altitude training of 2 months [10]. 
GENDER
There’s an evident gender disparity in the 
documentation of CVT at high altitude, with a 
significantly higher incidence of CVT in males [1]. Most 
of the stronger studies were done on stationed soldiers 
and male trekkers [2,3,5,6,7,8]. and majority of the 
case reports document male patients [11, 
12,15,16,17,18,19]. Mountaineering is a 
male-dominated sport [14]. Women have additional 
risk factors such as oral contraceptive pills and 
pregnancy that predisposes them to venous 
thrombosis. Reported cases of females developing CVT 
at HA always had an existing underlying risk factor. A 
young female developing sinus vein thrombosis at HA 
had a history of oral contraceptive use that she claimed 
to have stopped taken 3 years prior to the incident 
[10]. Similarly, Shrestha et al. reported another female 
with heterozygous mutation of Factor V Leiden and low 
plasma levels of protein S suffered from CVT at 5600m 
[13]. A 39-year-old female was reported to develop 
bilateral deep subcortical infarction in combination with 
Acute Mountain Sickness [9].
CONGENITAL THROMBOPHILIAS
A pre-existing prothrombotic state, such as congenital 
thrombophilias, appears to the most common risk 
factor for developing CVT in a HA setting. A systemic 
review showed 9 out of 14 reported cases had an 
underlying hypercoagulable state with secondary 
polycythemia and Factor V Leiden mutations being the 
most common [1]. Heterozygous Factor V Leiden 
mutation increases the risk of thromboembolism by 
seven fold, whereas homozygous mutation increases 
the risk by eight-fold [20]. Bolous et al reported a case 
of sudden onset of right sided hemiplegia and aphasia 
secondary to CVT at 3000m in a 42-year-old man with 
congenital protein C deficiency, while Nair et al shares 
a case of a patient with a Protein S levels of 36% 
(normally 70-123%) presenting with CVT coupled with 
DVT. Both cases were distinct for positive family history 
of hypercoagulability [17]. Grabe et al recorded a case 
of homonymous hemaniopia from deep CVT leading to 
infarction of the optic tract and lateral geniculate 
nucleus at 4800m with an underlying heterozygous 
Factor V Leiden mutation and elevated Factor VIII levels 
[18]. Nair et al reports a case of 35-year-old patient 
with both intra-arterial and venous thrombosis at 
multiple sites including the superior sagittal sinus with 
an increased Plasminogen Activator Inhibitor 1 (PAI-1) 
due to 4G/4G genotype polymorphism [7].  Hassan et 
al brings to attention a case of a rare association 
between protein S deficiency and 
hyperhomocysteinemia that resulted in severe deep 
CVT [12]. 
OTHER RISK FACTORS
Factors that predispose to CVT formation include 
infections, head trauma, malignancy and drugs with 
prothrombotic tendencies. On HA, additional risk 
factors to consider are dehydration, immobility, 
polycythemia and changes in hemostasis. Dehydration 
secondary to reduced water intake, increased physical 
exertion as well as vomiting and diarrhea due to AMS 
can predispose to increased hemoconcentration 
[9,13]. Hemoconcentration also increases due to 
eventual acclimatization which leads to polycythemia 
and increased blood viscosity. The process of 
acclimatization brings about numerous changes in 
blood physiology leading to a higher risk of thrombus 
formation. Whilst full acclimatization is achieved, 
hematocrit is believed to have increased by 50% [20]. 
Significant increase in hemoglobin levels, hematocrit 
and RBC count is reported in various studies done on 
HA [5, 6]. Increased blood viscosity increases mean 
PTT and causes endothelial damage leading to clot 
formation. Polycythemia also results in increased 
cerebral blood flow, subsequently increasing 
intracranial pressure which in turn disrupts the cerebral 
venous blood flow. Although most cases of CVT at HA 
are observed in lowlanders acutely exposed to high 
altitude conditions, a few cases have also been 
observed in well acclimatized individuals native to such 
conditions. A case of vein of Galen thrombosis was 
observed in a permanent citizen of the Tibetan plateau 
(4000m) with an additional risk factor of recent history 
of trauma (bilateral acetabular fracture), high blood 
pressure, history of smoking and hemoglobin of 191 
g/L [16]. Similar case of a well acclimatized man 
presenting with occlusion of superior sagittal and right 
transverse sinuses around his 45th day at 5000m 
altitude, with an additional risk factor of pre-existing 
brain sinus narrowing and anomalies [19]. 10%-30% of 
the population is believed to have structural brain sinus 
anomalies. Extreme cold can trigger coagulation 
cascade [23].
SUGGESTED MECHANISMS
The precise etiopathology of thrombosis at HA is 
obscure. The literature contains conflicting studies 
offering a wide array of plausible explanations regarding 
the underlying mechanisms that lead to a 
hypercoaguable state at HA. Hypoxia-induced 
customization of hemostasis and coagulation factors 
results in simultaneous changes in multiple 
components of blood, predisposing to thrombosis. 
ROLE OF INFLAMMATION
Gupta et al emphasized the presence of an active 
proinflammatory response to hypoxia employing innate 
and adaptive immune cells resulting in aggravated 
venous thrombosis. This proinflammatory state 
develops in response to HA due to the action of 
Hypoxia-induced factor 1-alpha (HIF-1a) on NLRP3 
gene expression leading to formation of NLRP3 
inflammasome [21]. This study documents the 
presence of NLRP3, caspase-1 and IL- β in individuals 
who formed venous thrombosis. Additionally, another 
contributing factor is believed to be 
endothelin-1-mediated and interleukin-6-mediated 
endothelial activation and related inflammatory 
response [15].  
  
ROLE OF FACTOR VIII, PAI-1 
AND PLATELET ACTIVITY
Kicken et al attributed the increase in thrombin levels 
mediated by increased Factor VIII levels to be the cause 
of increased hypercoagulability at HA. Factor VIII levels 
were presumed to be increased due to the oxidative 
stress in circulation due to tissue hypoxia, asserting 
that hypoxia alters the “redox status” of the blood [6]. 
This study also found that platelet aggregation was 
reduced at HA, attributing to increased ADP and 
epinephrine. Antithrombin levels, D-dimers and 
coagulation factors remained unchanged as compared 
to sea levels. Interestingly, subjects which were 
pretreated with Vitamin E had a reduced incidence of 
venous thrombosis [6]. On the other hand, Kotwal et al 
studied the effect of high altitude on hemostasis at 
induction, 3 months and 8 months and reported a 
significant rise in platelet count and platelet activation 
factors (BTG and PF4). This study also reported a 
significant rise in hemoglobin, PAI-1 activity and plasma 
fibrinogen, asserting a positive relationship between 
the latter two and postulating the significance of PAI-1 
in “tilting the balance” towards thrombosis by 
decreasing fibrinolytic activity. Kotwal et al also 
emphasized that platelet aggregation in the context of 
thrombosis was not a reliable method, instead BTG and 
PF4 measured on ELISA assay were more illustrative of 
platelet activity [5]. 
Martin et al contradicts aforementioned findings by 
analyzing the kinetics of clot formation using 
thromboelastography to study the effects of hypoxia at 
4250 m and 5300m on coagulation [3].  It was found 
that exposure to hypoxia decreases blood coagulability 
[3].
ROLE OF INCREASED SYMPATHETIC ACTIVITY
Hypoxia is also believed to trigger the body’s 
sympathetic response and increased sympathetic 
activity has a strong relationship with stroke [20, 22]. 
Constantly increased norepinephrine activates platelet 
hyperfunctioning leading to a hypercoagulable state 
[22]. 
Clinical Features and Diagnostic Challenges
There’s a considerable variation in the clinical features 
associated with CVT. Severity of the presentation is 
contingent with the extent of the thrombosis, sinuses 
involved and development of venous collaterals [12]. 
Most common signs and symptoms include 
headaches, focal neurological deficits, seizures and 
altered mental status [1, 2]. Other symptoms include 
papilledema and behavioral changes. Both cytotoxic 
and vasogenic cerebral edema are associated with CVT 
[28]. These present with an acute onset and the 
headaches are often associated with vomiting, 
confusion and loss of consciousness. Deep CVT 
involving the thalamus, basal ganglia and subcortical 
white matter presents as serious neurological 
emergency [12,16,18]. 
More common neurological conditions associated with 
high altitude are High-altitude headache (HAH), Acute 
mountain sickness (AMS) and High altitude cerebral 
edema (HACE). These render the accurate diagnosis 
difficult due to several overlapping clinical features. For 
example, HACE presents as altered mental status, 
ataxia of gait, and psychiatric changes that can lead to 
deep coma. Table 2 illustrates the clinical features of 
patients who developed CVT at HA. 
anticoagulation and rehabilitation [29]. Failure to 
anticoagulated results in poor prognosis [9, 29]. 25% 
of patients with CVT deteriorate despite adequate 
anticoagulation [2]. Overall mortality rate associated 
with CVT is 34.2% [29]. Bilateral CVT (which male up 
3%-8% of all CVT) and deep CVT present with severe 
clinical features and are associated with poor clinical 
outcome [2,9,16,18]. According to the International 
Study of Cerebral Vein and Dural Thrombosis (ISCVT) 
13% had poor neurological outcome whereas 4.3% 
were recorded to have died during the acute phase. 
Bushnaq et al demonstrated that the most significant 
predictor of poor prognosis to be altered or decreased 
mental status. Other indicators for poor prognosis are 
seizures, papilledema, hyponatremia (<139mEq/L), 
low platelet count (<225x109/L) and involvement of 
more than one sinus [2]. Endovascular therapy has 
been used as a salvage intervention, however there’s 
not much evidence to support its efficiency in 
decreasing mortality. Delaying thrombectomy can result 
in fibrosing of the thrombus leading to permanent 
neurological damage [2].
TREATMENT
 
Treatment of choice for CVT at HA is anticoagulation 
with subcutaneous Low Molecular Weight Heparin [32]. 
In the acute phase of the disease, first concern should 
be to stabilize and prevent cerebral herniation [28]. 
Decompressive surgery is strongly suggested for acute 
CVT with parenchymal involvement [32]. Use of 
acetazolamide, steroids and thrombolysis in acute CVT 
is discouraged [32]. For medically-refractory cases, 
mechanical thrombectomy can be considered [31]. 
Long term anticoagulation with warfarin or newer oral 
anticoagulants (NOACs) may be required for variable 
periods.
PROPHYLAXIS
LMWH and Warfarin are proven to be acceptable 
prophylaxis against hypercoagulabity at HA.  Use of oral 
anticoagulants after an episode of CVT to prevent 
further incidence has low evidence of impact and not 
recommended [32].
Oral Contraceptive Pills should be discontinued by 
females before embarking on a HA journey.
FUTURE DIRECTIONS
The exact incidence and mortality rate of CVT on a HA 
is unknown. Almost all epidemiological studies about 
CVT are based on normal altitude, not taking in account 
the additional risk factors associated with hypobaric 
hypoxia. Most high altitude studies were done on male, 
middle-aged soldiers or mountaineers without proper 
controls, this gives rise to bias and inaccuracy. 
Multi-center academic collaborations between 
institutions investigating incidence of high 
altitude-associated CVT can help improve the current 
understanding about involved risk factors. A case 
control study will be useful in identifying risk factors for 
high altitude CVT. Future intervention trials could be 
planned targeting high risk populations. Determining 
the precise altitude at which the risk of developing CVT 
increases significantly can help caution susceptible 
individuals. Although screening for thrombophilias is 
not recommended for CVT at normal altitude [32], 
studies showing a strong relationship between the two 
should prompt further research on whether 
thrombophilia screening should be incorporated in the 
diagnostic protocol for CVT cases presenting at a HA 
setting. Those set to experience hypobaric hypoxic 
conditions should also get routine blood counts to 
screen for polycythemia and thrombocytosis. Screening 
for Vitamin B12 and Folate levels can help detect a 
state of hyperhomocysteinemia. Health care 
professionals should also be trained to consider and 
diagnose CVT in patients with neurological symptoms. 
Availability of imaging modalities such as CT and MRI 
scan can lead to quicker diagnosis and treatment. More 
research should be focused on the underlying 
pathophysiology and mechanisms involved with 
hypoxia-associated CVT to create effective prophylaxis, 
protocols and treatment plans.
CONCLUSION
 
Cerebral Venous Thrombosis occurring at high altitude 
is a neurological emergency that requires timely 
diagnosis and treatment. It has complex underlying 
mechanisms and etiologies as well as numerous 
clinical presentations.  Understanding the predisposing 
factors to this phenomenon can lead to effective 
preventive measures, quicker diagnosis and 
management. Individuals with history of coagulation 
abnormalities should be screened for underlying 
thrombophilias and cautiously ascend to higher 
altitudes. CVT should be considered in all neurological 
clinical presentations at high altitude. High altitude 
trekkers should be educated on how to keep hydrated 
and avoid immobility, exposure to extreme cold and 
seeking immediate help for symptoms like headache 
and disturbed mental status. Patients with no 
contraindications to anticoagulation should be 
immediately anticoagulated with appropriate drugs.
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DIAGNOSIS
Neuroimaging plays a vital role in the diagnosis and 
clinical outcome [31]. Two most common imaging 
modalities used to confirm diagnosis of CVT are CT scan 
and MRI, and MRV when not visualized in MRI [1, 32]. 
There are alterations in the intensity of the thrombus 
depending on its age [31]. Most common sinuses to be 
affected is the superior sagittal sinus and transverse 
sinus [1, 2]. Kim et al weren’t able to locate any 
indication of thrombosis except for vasogenic edema 
with a hemorrhagic component on MRI [15]. D-dimer 
level can be effective to diagnose restricted sinus 
involvement or in older individuals, however, there is a 
chance of false negative results and its role in diagnosis 
remains controversial [24, 32]. Imaging modality of 
choice to visualize deep CVT is MRI T1W1 [12]. Family 
history of coagulation disorders should raise suspicion 
for CVT for anyone presenting with neurological findings 
at HA. Nair et al demonstrated that PA1-1 
polymorphism lead to widespread thrombosis at 
multiple sites including aorta, bilateral iliac arteries, 
middle cerebral artery and CVT of superior sagittal sinus 
[7].
PROGNOSIS
 
The main determinant of prognosis is timely diagnosis 
and treatment. Hemorrhage is a common sequela of 
CVT and worsens clinical outcome [11]. Most cases of 
CVT show good recovery with a combination of quick 
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nature of diagnosis and treatment and the extent of the 
thrombosis. Bilateral or extensive thrombosis coupled 
with underlying coagulation disorder is associated with 
poor prognosis. Understanding the pathophysiology and 
the risk factors can help prevent incidence of CVT at 
high altitude as well as educate physicians and 
climbers about prompt diagnosis, treatment, screening 
and appropriate preventive measures. 
SEARCH METHODOLOGY
Comprehensive literature search was done on search 
engines PubMed and Google Scholar using the 
keywords “Cerebral Venous Thrombosis”, “High 
Altitude” and “Venous Thrombosis”. The following 
search query was used in PubMed: (“Cerebral Venous 
Thrombosis” [MeSh]) OR (Cerebral Venous 
Thrombosis[Title] AND High Altitude[Title]) OR (Cerebral 
Venous Thrombosis[Title] OR High Altitude) OR 
(Cerebral Venous Thrombosis at High Altitude[Title]). 
Inclusion criteria consisted of articles from journals that 
were PubMed indexed and published in the last 20 
years. A total of 40 articles were reviewed, out of which 
32 were included in the final paper. The references in 
papers found to be eligible were taken into account and 
screened for relevant information. The full text of all 
acceptable papers was accessed and read thoroughly. 
A comprehensive table of all pertinent information was 
made for easy access during article writing. Literature 
related to pathophysiology of venous thrombosis due to 
hypoxia was selected according to its relevance and 
recentness.
HIGH ALTITUDE (HA)
Barometric pressure decreases at an exponential rate 
as higher altitudes are reached, leading to a decrease 
in the partial pressure of Oxygen, which results in brain 
receiving less oxygen, hence inducing hypoxia [4]. CVT 
has been mostly described to occur between altitudes 
ranging from 2500m to 5500m [1]. It has been 
proposed that activation of coagulation factors leading 
to a prothrombotic state is rate dependent, i.e the 
more rapid the ascent to HA, higher the risk of 
developing CVT [5, 10].  Comparatively, gradual ascent 
to HA and well-acclimatized individuals pose a lesser 
risk of thrombosis. A study held in India compared 
1692 patient profiles comparing incidence of 
thrombosis in extremely HA (>5000m) and sea levels 
found that there was a 30 times higher incidence of 
CVT at HA [8]. Similarly, a study done on healthy, young 
soldiers at 3500m found a 30 times higher incidence 
of thrombosis [5].  Another study found that lowlanders 
posted at 3883m had 30-44 times increased 
incidence of deep vein thrombosis [6]. It was suggested 
that acute exposure to hypoxia solely cannot 
predispose to thrombosis without significant underlying 
shift in hemostasis [11]. There is a lack of good studies 
to determine the exact cause of hypercoagulability in 
HA especially since most of current studies in the West 
are performed in artificially simulated hypoxic 
environment. CVT can occur in lower than average 
altitude in people with pre-existing underlying 
prothrombotic state. Prolonged duration of stay is also 
associated with higher incidence of CVT as illustrated 
by various case reports. Table 1 shows incidents of CVT 
in high altitude.
TABLE 1: CASE REPORTS AND STUDIES WITH 
ASSOCIATED ALTITUDES AT WHICH CVT INCIDENCE 
OCCURRED.
AGE
At HA, CVT is typically observed in young to middle aged 
individuals [1]. Extremes of ages have also been 
reported with a 75-year-old man with an underlying 
case of hyperhomocysteinemia developing deep CVT at 
an altitude of 2200 m for 3 days [12] and a 
19-year-old female developing sinus vein thrombosis 
after a high altitude training of 2 months [10]. 
GENDER
There’s an evident gender disparity in the 
documentation of CVT at high altitude, with a 
significantly higher incidence of CVT in males [1]. Most 
of the stronger studies were done on stationed soldiers 
and male trekkers [2,3,5,6,7,8]. and majority of the 
case reports document male patients [11, 
12,15,16,17,18,19]. Mountaineering is a 
male-dominated sport [14]. Women have additional 
risk factors such as oral contraceptive pills and 
pregnancy that predisposes them to venous 
thrombosis. Reported cases of females developing CVT 
at HA always had an existing underlying risk factor. A 
young female developing sinus vein thrombosis at HA 
had a history of oral contraceptive use that she claimed 
to have stopped taken 3 years prior to the incident 
[10]. Similarly, Shrestha et al. reported another female 
with heterozygous mutation of Factor V Leiden and low 
plasma levels of protein S suffered from CVT at 5600m 
[13]. A 39-year-old female was reported to develop 
bilateral deep subcortical infarction in combination with 
Acute Mountain Sickness [9].
CONGENITAL THROMBOPHILIAS
A pre-existing prothrombotic state, such as congenital 
thrombophilias, appears to the most common risk 
factor for developing CVT in a HA setting. A systemic 
review showed 9 out of 14 reported cases had an 
underlying hypercoagulable state with secondary 
polycythemia and Factor V Leiden mutations being the 
most common [1]. Heterozygous Factor V Leiden 
mutation increases the risk of thromboembolism by 
seven fold, whereas homozygous mutation increases 
the risk by eight-fold [20]. Bolous et al reported a case 
of sudden onset of right sided hemiplegia and aphasia 
secondary to CVT at 3000m in a 42-year-old man with 
congenital protein C deficiency, while Nair et al shares 
a case of a patient with a Protein S levels of 36% 
(normally 70-123%) presenting with CVT coupled with 
DVT. Both cases were distinct for positive family history 
of hypercoagulability [17]. Grabe et al recorded a case 
of homonymous hemaniopia from deep CVT leading to 
infarction of the optic tract and lateral geniculate 
nucleus at 4800m with an underlying heterozygous 
Factor V Leiden mutation and elevated Factor VIII levels 
[18]. Nair et al reports a case of 35-year-old patient 
with both intra-arterial and venous thrombosis at 
multiple sites including the superior sagittal sinus with 
an increased Plasminogen Activator Inhibitor 1 (PAI-1) 
due to 4G/4G genotype polymorphism [7].  Hassan et 
al brings to attention a case of a rare association 
between protein S deficiency and 
hyperhomocysteinemia that resulted in severe deep 
CVT [12]. 
OTHER RISK FACTORS
Factors that predispose to CVT formation include 
infections, head trauma, malignancy and drugs with 
prothrombotic tendencies. On HA, additional risk 
factors to consider are dehydration, immobility, 
polycythemia and changes in hemostasis. Dehydration 
secondary to reduced water intake, increased physical 
exertion as well as vomiting and diarrhea due to AMS 
can predispose to increased hemoconcentration 
[9,13]. Hemoconcentration also increases due to 
eventual acclimatization which leads to polycythemia 
and increased blood viscosity. The process of 
acclimatization brings about numerous changes in 
blood physiology leading to a higher risk of thrombus 
formation. Whilst full acclimatization is achieved, 
hematocrit is believed to have increased by 50% [20]. 
Significant increase in hemoglobin levels, hematocrit 
and RBC count is reported in various studies done on 
HA [5, 6]. Increased blood viscosity increases mean 
PTT and causes endothelial damage leading to clot 
formation. Polycythemia also results in increased 
cerebral blood flow, subsequently increasing 
intracranial pressure which in turn disrupts the cerebral 
venous blood flow. Although most cases of CVT at HA 
are observed in lowlanders acutely exposed to high 
altitude conditions, a few cases have also been 
observed in well acclimatized individuals native to such 
conditions. A case of vein of Galen thrombosis was 
observed in a permanent citizen of the Tibetan plateau 
(4000m) with an additional risk factor of recent history 
of trauma (bilateral acetabular fracture), high blood 
pressure, history of smoking and hemoglobin of 191 
g/L [16]. Similar case of a well acclimatized man 
presenting with occlusion of superior sagittal and right 
transverse sinuses around his 45th day at 5000m 
altitude, with an additional risk factor of pre-existing 
brain sinus narrowing and anomalies [19]. 10%-30% of 
the population is believed to have structural brain sinus 
anomalies. Extreme cold can trigger coagulation 
cascade [23].
SUGGESTED MECHANISMS
The precise etiopathology of thrombosis at HA is 
obscure. The literature contains conflicting studies 
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offering a wide array of plausible explanations regarding 
the underlying mechanisms that lead to a 
hypercoaguable state at HA. Hypoxia-induced 
customization of hemostasis and coagulation factors 
results in simultaneous changes in multiple 
components of blood, predisposing to thrombosis. 
ROLE OF INFLAMMATION
Gupta et al emphasized the presence of an active 
proinflammatory response to hypoxia employing innate 
and adaptive immune cells resulting in aggravated 
venous thrombosis. This proinflammatory state 
develops in response to HA due to the action of 
Hypoxia-induced factor 1-alpha (HIF-1a) on NLRP3 
gene expression leading to formation of NLRP3 
inflammasome [21]. This study documents the 
presence of NLRP3, caspase-1 and IL- β in individuals 
who formed venous thrombosis. Additionally, another 
contributing factor is believed to be 
endothelin-1-mediated and interleukin-6-mediated 
endothelial activation and related inflammatory 
response [15].  
  
ROLE OF FACTOR VIII, PAI-1 
AND PLATELET ACTIVITY
Kicken et al attributed the increase in thrombin levels 
mediated by increased Factor VIII levels to be the cause 
of increased hypercoagulability at HA. Factor VIII levels 
were presumed to be increased due to the oxidative 
stress in circulation due to tissue hypoxia, asserting 
that hypoxia alters the “redox status” of the blood [6]. 
This study also found that platelet aggregation was 
reduced at HA, attributing to increased ADP and 
epinephrine. Antithrombin levels, D-dimers and 
coagulation factors remained unchanged as compared 
to sea levels. Interestingly, subjects which were 
pretreated with Vitamin E had a reduced incidence of 
venous thrombosis [6]. On the other hand, Kotwal et al 
studied the effect of high altitude on hemostasis at 
induction, 3 months and 8 months and reported a 
significant rise in platelet count and platelet activation 
factors (BTG and PF4). This study also reported a 
significant rise in hemoglobin, PAI-1 activity and plasma 
fibrinogen, asserting a positive relationship between 
the latter two and postulating the significance of PAI-1 
in “tilting the balance” towards thrombosis by 
decreasing fibrinolytic activity. Kotwal et al also 
emphasized that platelet aggregation in the context of 
thrombosis was not a reliable method, instead BTG and 
PF4 measured on ELISA assay were more illustrative of 
platelet activity [5]. 
Martin et al contradicts aforementioned findings by 
analyzing the kinetics of clot formation using 
thromboelastography to study the effects of hypoxia at 
4250 m and 5300m on coagulation [3].  It was found 
that exposure to hypoxia decreases blood coagulability 
[3].
ROLE OF INCREASED SYMPATHETIC ACTIVITY
Hypoxia is also believed to trigger the body’s 
sympathetic response and increased sympathetic 
activity has a strong relationship with stroke [20, 22]. 
Constantly increased norepinephrine activates platelet 
hyperfunctioning leading to a hypercoagulable state 
[22]. 
Clinical Features and Diagnostic Challenges
There’s a considerable variation in the clinical features 
associated with CVT. Severity of the presentation is 
contingent with the extent of the thrombosis, sinuses 
involved and development of venous collaterals [12]. 
Most common signs and symptoms include 
headaches, focal neurological deficits, seizures and 
altered mental status [1, 2]. Other symptoms include 
papilledema and behavioral changes. Both cytotoxic 
and vasogenic cerebral edema are associated with CVT 
[28]. These present with an acute onset and the 
headaches are often associated with vomiting, 
confusion and loss of consciousness. Deep CVT 
involving the thalamus, basal ganglia and subcortical 
white matter presents as serious neurological 
emergency [12,16,18]. 
More common neurological conditions associated with 
high altitude are High-altitude headache (HAH), Acute 
mountain sickness (AMS) and High altitude cerebral 
edema (HACE). These render the accurate diagnosis 
difficult due to several overlapping clinical features. For 
example, HACE presents as altered mental status, 
ataxia of gait, and psychiatric changes that can lead to 
deep coma. Table 2 illustrates the clinical features of 
patients who developed CVT at HA. 
anticoagulation and rehabilitation [29]. Failure to 
anticoagulated results in poor prognosis [9, 29]. 25% 
of patients with CVT deteriorate despite adequate 
anticoagulation [2]. Overall mortality rate associated 
with CVT is 34.2% [29]. Bilateral CVT (which male up 
3%-8% of all CVT) and deep CVT present with severe 
clinical features and are associated with poor clinical 
outcome [2,9,16,18]. According to the International 
Study of Cerebral Vein and Dural Thrombosis (ISCVT) 
13% had poor neurological outcome whereas 4.3% 
were recorded to have died during the acute phase. 
Bushnaq et al demonstrated that the most significant 
predictor of poor prognosis to be altered or decreased 
mental status. Other indicators for poor prognosis are 
seizures, papilledema, hyponatremia (<139mEq/L), 
low platelet count (<225x109/L) and involvement of 
more than one sinus [2]. Endovascular therapy has 
been used as a salvage intervention, however there’s 
not much evidence to support its efficiency in 
decreasing mortality. Delaying thrombectomy can result 
in fibrosing of the thrombus leading to permanent 
neurological damage [2].
TREATMENT
 
Treatment of choice for CVT at HA is anticoagulation 
with subcutaneous Low Molecular Weight Heparin [32]. 
In the acute phase of the disease, first concern should 
be to stabilize and prevent cerebral herniation [28]. 
Decompressive surgery is strongly suggested for acute 
CVT with parenchymal involvement [32]. Use of 
acetazolamide, steroids and thrombolysis in acute CVT 
is discouraged [32]. For medically-refractory cases, 
mechanical thrombectomy can be considered [31]. 
Long term anticoagulation with warfarin or newer oral 
anticoagulants (NOACs) may be required for variable 
periods.
PROPHYLAXIS
LMWH and Warfarin are proven to be acceptable 
prophylaxis against hypercoagulabity at HA.  Use of oral 
anticoagulants after an episode of CVT to prevent 
further incidence has low evidence of impact and not 
recommended [32].
Oral Contraceptive Pills should be discontinued by 
females before embarking on a HA journey.
FUTURE DIRECTIONS
The exact incidence and mortality rate of CVT on a HA 
is unknown. Almost all epidemiological studies about 
CVT are based on normal altitude, not taking in account 
the additional risk factors associated with hypobaric 
hypoxia. Most high altitude studies were done on male, 
middle-aged soldiers or mountaineers without proper 
controls, this gives rise to bias and inaccuracy. 
Multi-center academic collaborations between 
institutions investigating incidence of high 
altitude-associated CVT can help improve the current 
understanding about involved risk factors. A case 
control study will be useful in identifying risk factors for 
high altitude CVT. Future intervention trials could be 
planned targeting high risk populations. Determining 
the precise altitude at which the risk of developing CVT 
increases significantly can help caution susceptible 
individuals. Although screening for thrombophilias is 
not recommended for CVT at normal altitude [32], 
studies showing a strong relationship between the two 
should prompt further research on whether 
thrombophilia screening should be incorporated in the 
diagnostic protocol for CVT cases presenting at a HA 
setting. Those set to experience hypobaric hypoxic 
conditions should also get routine blood counts to 
screen for polycythemia and thrombocytosis. Screening 
for Vitamin B12 and Folate levels can help detect a 
state of hyperhomocysteinemia. Health care 
professionals should also be trained to consider and 
diagnose CVT in patients with neurological symptoms. 
Availability of imaging modalities such as CT and MRI 
scan can lead to quicker diagnosis and treatment. More 
research should be focused on the underlying 
pathophysiology and mechanisms involved with 
hypoxia-associated CVT to create effective prophylaxis, 
protocols and treatment plans.
CONCLUSION
 
Cerebral Venous Thrombosis occurring at high altitude 
is a neurological emergency that requires timely 
diagnosis and treatment. It has complex underlying 
mechanisms and etiologies as well as numerous 
clinical presentations.  Understanding the predisposing 
factors to this phenomenon can lead to effective 
preventive measures, quicker diagnosis and 
management. Individuals with history of coagulation 
abnormalities should be screened for underlying 
thrombophilias and cautiously ascend to higher 
altitudes. CVT should be considered in all neurological 
clinical presentations at high altitude. High altitude 
trekkers should be educated on how to keep hydrated 
and avoid immobility, exposure to extreme cold and 
seeking immediate help for symptoms like headache 
and disturbed mental status. Patients with no 
contraindications to anticoagulation should be 
immediately anticoagulated with appropriate drugs.
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DIAGNOSIS
Neuroimaging plays a vital role in the diagnosis and 
clinical outcome [31]. Two most common imaging 
modalities used to confirm diagnosis of CVT are CT scan 
and MRI, and MRV when not visualized in MRI [1, 32]. 
There are alterations in the intensity of the thrombus 
depending on its age [31]. Most common sinuses to be 
affected is the superior sagittal sinus and transverse 
sinus [1, 2]. Kim et al weren’t able to locate any 
indication of thrombosis except for vasogenic edema 
with a hemorrhagic component on MRI [15]. D-dimer 
level can be effective to diagnose restricted sinus 
involvement or in older individuals, however, there is a 
chance of false negative results and its role in diagnosis 
remains controversial [24, 32]. Imaging modality of 
choice to visualize deep CVT is MRI T1W1 [12]. Family 
history of coagulation disorders should raise suspicion 
for CVT for anyone presenting with neurological findings 
at HA. Nair et al demonstrated that PA1-1 
polymorphism lead to widespread thrombosis at 
multiple sites including aorta, bilateral iliac arteries, 
middle cerebral artery and CVT of superior sagittal sinus 
[7].
PROGNOSIS
 
The main determinant of prognosis is timely diagnosis 
and treatment. Hemorrhage is a common sequela of 
CVT and worsens clinical outcome [11]. Most cases of 
CVT show good recovery with a combination of quick 
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nature of diagnosis and treatment and the extent of the 
thrombosis. Bilateral or extensive thrombosis coupled 
with underlying coagulation disorder is associated with 
poor prognosis. Understanding the pathophysiology and 
the risk factors can help prevent incidence of CVT at 
high altitude as well as educate physicians and 
climbers about prompt diagnosis, treatment, screening 
and appropriate preventive measures. 
SEARCH METHODOLOGY
Comprehensive literature search was done on search 
engines PubMed and Google Scholar using the 
keywords “Cerebral Venous Thrombosis”, “High 
Altitude” and “Venous Thrombosis”. The following 
search query was used in PubMed: (“Cerebral Venous 
Thrombosis” [MeSh]) OR (Cerebral Venous 
Thrombosis[Title] AND High Altitude[Title]) OR (Cerebral 
Venous Thrombosis[Title] OR High Altitude) OR 
(Cerebral Venous Thrombosis at High Altitude[Title]). 
Inclusion criteria consisted of articles from journals that 
were PubMed indexed and published in the last 20 
years. A total of 40 articles were reviewed, out of which 
32 were included in the final paper. The references in 
papers found to be eligible were taken into account and 
screened for relevant information. The full text of all 
acceptable papers was accessed and read thoroughly. 
A comprehensive table of all pertinent information was 
made for easy access during article writing. Literature 
related to pathophysiology of venous thrombosis due to 
hypoxia was selected according to its relevance and 
recentness.
HIGH ALTITUDE (HA)
Barometric pressure decreases at an exponential rate 
as higher altitudes are reached, leading to a decrease 
in the partial pressure of Oxygen, which results in brain 
receiving less oxygen, hence inducing hypoxia [4]. CVT 
has been mostly described to occur between altitudes 
ranging from 2500m to 5500m [1]. It has been 
proposed that activation of coagulation factors leading 
to a prothrombotic state is rate dependent, i.e the 
more rapid the ascent to HA, higher the risk of 
developing CVT [5, 10].  Comparatively, gradual ascent 
to HA and well-acclimatized individuals pose a lesser 
risk of thrombosis. A study held in India compared 
1692 patient profiles comparing incidence of 
thrombosis in extremely HA (>5000m) and sea levels 
found that there was a 30 times higher incidence of 
CVT at HA [8]. Similarly, a study done on healthy, young 
soldiers at 3500m found a 30 times higher incidence 
of thrombosis [5].  Another study found that lowlanders 
posted at 3883m had 30-44 times increased 
incidence of deep vein thrombosis [6]. It was suggested 
that acute exposure to hypoxia solely cannot 
predispose to thrombosis without significant underlying 
shift in hemostasis [11]. There is a lack of good studies 
to determine the exact cause of hypercoagulability in 
HA especially since most of current studies in the West 
are performed in artificially simulated hypoxic 
environment. CVT can occur in lower than average 
altitude in people with pre-existing underlying 
prothrombotic state. Prolonged duration of stay is also 
associated with higher incidence of CVT as illustrated 
by various case reports. Table 1 shows incidents of CVT 
in high altitude.
TABLE 1: CASE REPORTS AND STUDIES WITH 
ASSOCIATED ALTITUDES AT WHICH CVT INCIDENCE 
OCCURRED.
AGE
At HA, CVT is typically observed in young to middle aged 
individuals [1]. Extremes of ages have also been 
reported with a 75-year-old man with an underlying 
case of hyperhomocysteinemia developing deep CVT at 
an altitude of 2200 m for 3 days [12] and a 
19-year-old female developing sinus vein thrombosis 
after a high altitude training of 2 months [10]. 
GENDER
There’s an evident gender disparity in the 
documentation of CVT at high altitude, with a 
significantly higher incidence of CVT in males [1]. Most 
of the stronger studies were done on stationed soldiers 
and male trekkers [2,3,5,6,7,8]. and majority of the 
case reports document male patients [11, 
12,15,16,17,18,19]. Mountaineering is a 
male-dominated sport [14]. Women have additional 
risk factors such as oral contraceptive pills and 
pregnancy that predisposes them to venous 
thrombosis. Reported cases of females developing CVT 
at HA always had an existing underlying risk factor. A 
young female developing sinus vein thrombosis at HA 
had a history of oral contraceptive use that she claimed 
to have stopped taken 3 years prior to the incident 
[10]. Similarly, Shrestha et al. reported another female 
with heterozygous mutation of Factor V Leiden and low 
plasma levels of protein S suffered from CVT at 5600m 
[13]. A 39-year-old female was reported to develop 
bilateral deep subcortical infarction in combination with 
Acute Mountain Sickness [9].
CONGENITAL THROMBOPHILIAS
A pre-existing prothrombotic state, such as congenital 
thrombophilias, appears to the most common risk 
factor for developing CVT in a HA setting. A systemic 
review showed 9 out of 14 reported cases had an 
underlying hypercoagulable state with secondary 
polycythemia and Factor V Leiden mutations being the 
most common [1]. Heterozygous Factor V Leiden 
mutation increases the risk of thromboembolism by 
seven fold, whereas homozygous mutation increases 
the risk by eight-fold [20]. Bolous et al reported a case 
of sudden onset of right sided hemiplegia and aphasia 
secondary to CVT at 3000m in a 42-year-old man with 
congenital protein C deficiency, while Nair et al shares 
a case of a patient with a Protein S levels of 36% 
(normally 70-123%) presenting with CVT coupled with 
DVT. Both cases were distinct for positive family history 
of hypercoagulability [17]. Grabe et al recorded a case 
of homonymous hemaniopia from deep CVT leading to 
infarction of the optic tract and lateral geniculate 
nucleus at 4800m with an underlying heterozygous 
Factor V Leiden mutation and elevated Factor VIII levels 
[18]. Nair et al reports a case of 35-year-old patient 
with both intra-arterial and venous thrombosis at 
multiple sites including the superior sagittal sinus with 
an increased Plasminogen Activator Inhibitor 1 (PAI-1) 
due to 4G/4G genotype polymorphism [7].  Hassan et 
al brings to attention a case of a rare association 
between protein S deficiency and 
hyperhomocysteinemia that resulted in severe deep 
CVT [12]. 
OTHER RISK FACTORS
Factors that predispose to CVT formation include 
infections, head trauma, malignancy and drugs with 
prothrombotic tendencies. On HA, additional risk 
factors to consider are dehydration, immobility, 
polycythemia and changes in hemostasis. Dehydration 
secondary to reduced water intake, increased physical 
exertion as well as vomiting and diarrhea due to AMS 
can predispose to increased hemoconcentration 
[9,13]. Hemoconcentration also increases due to 
eventual acclimatization which leads to polycythemia 
and increased blood viscosity. The process of 
acclimatization brings about numerous changes in 
blood physiology leading to a higher risk of thrombus 
formation. Whilst full acclimatization is achieved, 
hematocrit is believed to have increased by 50% [20]. 
Significant increase in hemoglobin levels, hematocrit 
and RBC count is reported in various studies done on 
HA [5, 6]. Increased blood viscosity increases mean 
PTT and causes endothelial damage leading to clot 
formation. Polycythemia also results in increased 
cerebral blood flow, subsequently increasing 
intracranial pressure which in turn disrupts the cerebral 
venous blood flow. Although most cases of CVT at HA 
are observed in lowlanders acutely exposed to high 
altitude conditions, a few cases have also been 
observed in well acclimatized individuals native to such 
conditions. A case of vein of Galen thrombosis was 
observed in a permanent citizen of the Tibetan plateau 
(4000m) with an additional risk factor of recent history 
of trauma (bilateral acetabular fracture), high blood 
pressure, history of smoking and hemoglobin of 191 
g/L [16]. Similar case of a well acclimatized man 
presenting with occlusion of superior sagittal and right 
transverse sinuses around his 45th day at 5000m 
altitude, with an additional risk factor of pre-existing 
brain sinus narrowing and anomalies [19]. 10%-30% of 
the population is believed to have structural brain sinus 
anomalies. Extreme cold can trigger coagulation 
cascade [23].
SUGGESTED MECHANISMS
The precise etiopathology of thrombosis at HA is 
obscure. The literature contains conflicting studies 
offering a wide array of plausible explanations regarding 
the underlying mechanisms that lead to a 
hypercoaguable state at HA. Hypoxia-induced 
customization of hemostasis and coagulation factors 
results in simultaneous changes in multiple 
components of blood, predisposing to thrombosis. 
ROLE OF INFLAMMATION
Gupta et al emphasized the presence of an active 
proinflammatory response to hypoxia employing innate 
and adaptive immune cells resulting in aggravated 
venous thrombosis. This proinflammatory state 
develops in response to HA due to the action of 
Hypoxia-induced factor 1-alpha (HIF-1a) on NLRP3 
gene expression leading to formation of NLRP3 
inflammasome [21]. This study documents the 
presence of NLRP3, caspase-1 and IL- β in individuals 
who formed venous thrombosis. Additionally, another 
contributing factor is believed to be 
endothelin-1-mediated and interleukin-6-mediated 
endothelial activation and related inflammatory 
response [15].  
  
ROLE OF FACTOR VIII, PAI-1 
AND PLATELET ACTIVITY
Kicken et al attributed the increase in thrombin levels 
mediated by increased Factor VIII levels to be the cause 
of increased hypercoagulability at HA. Factor VIII levels 
were presumed to be increased due to the oxidative 
stress in circulation due to tissue hypoxia, asserting 
that hypoxia alters the “redox status” of the blood [6]. 
This study also found that platelet aggregation was 
reduced at HA, attributing to increased ADP and 
epinephrine. Antithrombin levels, D-dimers and 
coagulation factors remained unchanged as compared 
to sea levels. Interestingly, subjects which were 
pretreated with Vitamin E had a reduced incidence of 
venous thrombosis [6]. On the other hand, Kotwal et al 
studied the effect of high altitude on hemostasis at 
induction, 3 months and 8 months and reported a 
significant rise in platelet count and platelet activation 
factors (BTG and PF4). This study also reported a 
significant rise in hemoglobin, PAI-1 activity and plasma 
fibrinogen, asserting a positive relationship between 
the latter two and postulating the significance of PAI-1 
in “tilting the balance” towards thrombosis by 
decreasing fibrinolytic activity. Kotwal et al also 
emphasized that platelet aggregation in the context of 
thrombosis was not a reliable method, instead BTG and 
PF4 measured on ELISA assay were more illustrative of 
platelet activity [5]. 
Martin et al contradicts aforementioned findings by 
analyzing the kinetics of clot formation using 
thromboelastography to study the effects of hypoxia at 
4250 m and 5300m on coagulation [3].  It was found 
that exposure to hypoxia decreases blood coagulability 
[3].
ROLE OF INCREASED SYMPATHETIC ACTIVITY
Hypoxia is also believed to trigger the body’s 
sympathetic response and increased sympathetic 
activity has a strong relationship with stroke [20, 22]. 
Constantly increased norepinephrine activates platelet 
hyperfunctioning leading to a hypercoagulable state 
[22]. 
Clinical Features and Diagnostic Challenges
There’s a considerable variation in the clinical features 
associated with CVT. Severity of the presentation is 
contingent with the extent of the thrombosis, sinuses 
involved and development of venous collaterals [12]. 
Most common signs and symptoms include 
headaches, focal neurological deficits, seizures and 
altered mental status [1, 2]. Other symptoms include 
papilledema and behavioral changes. Both cytotoxic 
and vasogenic cerebral edema are associated with CVT 
[28]. These present with an acute onset and the 
headaches are often associated with vomiting, 
confusion and loss of consciousness. Deep CVT 
involving the thalamus, basal ganglia and subcortical 
white matter presents as serious neurological 
emergency [12,16,18]. 
More common neurological conditions associated with 
high altitude are High-altitude headache (HAH), Acute 
mountain sickness (AMS) and High altitude cerebral 
edema (HACE). These render the accurate diagnosis 
difficult due to several overlapping clinical features. For 
example, HACE presents as altered mental status, 
ataxia of gait, and psychiatric changes that can lead to 
deep coma. Table 2 illustrates the clinical features of 
patients who developed CVT at HA. 
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anticoagulation and rehabilitation [29]. Failure to 
anticoagulated results in poor prognosis [9, 29]. 25% 
of patients with CVT deteriorate despite adequate 
anticoagulation [2]. Overall mortality rate associated 
with CVT is 34.2% [29]. Bilateral CVT (which male up 
3%-8% of all CVT) and deep CVT present with severe 
clinical features and are associated with poor clinical 
outcome [2,9,16,18]. According to the International 
Study of Cerebral Vein and Dural Thrombosis (ISCVT) 
13% had poor neurological outcome whereas 4.3% 
were recorded to have died during the acute phase. 
Bushnaq et al demonstrated that the most significant 
predictor of poor prognosis to be altered or decreased 
mental status. Other indicators for poor prognosis are 
seizures, papilledema, hyponatremia (<139mEq/L), 
low platelet count (<225x109/L) and involvement of 
more than one sinus [2]. Endovascular therapy has 
been used as a salvage intervention, however there’s 
not much evidence to support its efficiency in 
decreasing mortality. Delaying thrombectomy can result 
in fibrosing of the thrombus leading to permanent 
neurological damage [2].
TREATMENT
 
Treatment of choice for CVT at HA is anticoagulation 
with subcutaneous Low Molecular Weight Heparin [32]. 
In the acute phase of the disease, first concern should 
be to stabilize and prevent cerebral herniation [28]. 
Decompressive surgery is strongly suggested for acute 
CVT with parenchymal involvement [32]. Use of 
acetazolamide, steroids and thrombolysis in acute CVT 
is discouraged [32]. For medically-refractory cases, 
mechanical thrombectomy can be considered [31]. 
Long term anticoagulation with warfarin or newer oral 
anticoagulants (NOACs) may be required for variable 
periods.
PROPHYLAXIS
LMWH and Warfarin are proven to be acceptable 
prophylaxis against hypercoagulabity at HA.  Use of oral 
anticoagulants after an episode of CVT to prevent 
further incidence has low evidence of impact and not 
recommended [32].
Oral Contraceptive Pills should be discontinued by 
females before embarking on a HA journey.
FUTURE DIRECTIONS
The exact incidence and mortality rate of CVT on a HA 
is unknown. Almost all epidemiological studies about 
CVT are based on normal altitude, not taking in account 
the additional risk factors associated with hypobaric 
hypoxia. Most high altitude studies were done on male, 
middle-aged soldiers or mountaineers without proper 
controls, this gives rise to bias and inaccuracy. 
Multi-center academic collaborations between 
institutions investigating incidence of high 
altitude-associated CVT can help improve the current 
understanding about involved risk factors. A case 
control study will be useful in identifying risk factors for 
high altitude CVT. Future intervention trials could be 
planned targeting high risk populations. Determining 
the precise altitude at which the risk of developing CVT 
increases significantly can help caution susceptible 
individuals. Although screening for thrombophilias is 
not recommended for CVT at normal altitude [32], 
studies showing a strong relationship between the two 
should prompt further research on whether 
thrombophilia screening should be incorporated in the 
diagnostic protocol for CVT cases presenting at a HA 
setting. Those set to experience hypobaric hypoxic 
conditions should also get routine blood counts to 
screen for polycythemia and thrombocytosis. Screening 
for Vitamin B12 and Folate levels can help detect a 
state of hyperhomocysteinemia. Health care 
professionals should also be trained to consider and 
diagnose CVT in patients with neurological symptoms. 
Availability of imaging modalities such as CT and MRI 
scan can lead to quicker diagnosis and treatment. More 
research should be focused on the underlying 
pathophysiology and mechanisms involved with 
hypoxia-associated CVT to create effective prophylaxis, 
protocols and treatment plans.
CONCLUSION
 
Cerebral Venous Thrombosis occurring at high altitude 
is a neurological emergency that requires timely 
diagnosis and treatment. It has complex underlying 
mechanisms and etiologies as well as numerous 
clinical presentations.  Understanding the predisposing 
factors to this phenomenon can lead to effective 
preventive measures, quicker diagnosis and 
management. Individuals with history of coagulation 
abnormalities should be screened for underlying 
thrombophilias and cautiously ascend to higher 
altitudes. CVT should be considered in all neurological 
clinical presentations at high altitude. High altitude 
trekkers should be educated on how to keep hydrated 
and avoid immobility, exposure to extreme cold and 
seeking immediate help for symptoms like headache 
and disturbed mental status. Patients with no 
contraindications to anticoagulation should be 
immediately anticoagulated with appropriate drugs.
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DIAGNOSIS
Neuroimaging plays a vital role in the diagnosis and 
clinical outcome [31]. Two most common imaging 
modalities used to confirm diagnosis of CVT are CT scan 
and MRI, and MRV when not visualized in MRI [1, 32]. 
There are alterations in the intensity of the thrombus 
depending on its age [31]. Most common sinuses to be 
affected is the superior sagittal sinus and transverse 
sinus [1, 2]. Kim et al weren’t able to locate any 
indication of thrombosis except for vasogenic edema 
with a hemorrhagic component on MRI [15]. D-dimer 
level can be effective to diagnose restricted sinus 
involvement or in older individuals, however, there is a 
chance of false negative results and its role in diagnosis 
 
PUBLICATION  CLINICAL FEATURES 
BOLOUS ET AL11 Sudden onset of right hemiplegia, aphasia, 
right facial droop and tonic-clonic seizures 
KIM ET AL15 Weakness in right arm and hand coupled with 
headache. 
HASSAN ET AL12 Global headaches and vomiting for 6 days 
CHENG ET AL9 Headache, dizziness and vomiting, 
drowsiness and GCS of 8. Tetraplegia. 
TORGOVICKY ET AL10 Frontal headache 
TE DP ET AL16 Reduced consciousness and reduced muscle 
strength. 
NAIR ET AL17S Presentation: Sudden onset severe bifrontal 
headache, vomiting and drowsiness. 
Day 6: partial motor seizures of right face and 
right arm. 
Day 9: right sided flaccid hemiplegia with 
cranial nerve VII involvement. 
  
GRABE ET AL18 Intermittent headaches and somnolence 
followed by right homonymous hemianopia 
and right hemiparesis along with right hemi-
sensory deficit.   
SAITO ET AL19 Gait disturbance, aphasia, visual field 
narrowing, agraphia, coordination deficit and 
paresthesia of upper limbs. 
SHRESTHA ET AL13 Sudden onset headache, aphasia and right 
upper quadrantanopia. 
NAIR ET AL7 Altered mental status and seizures.  
SKAIAA AND STAVE27 Severe headache, vomiting and mild 
drowsiness on two separate occasions (2001 
and 2004) 
 
TABLE 2: PUBLICATIONS CITING CVT INCIDENCE AT HA WITH ASSOCIATED CLINICAL FEATURES.
remains controversial [24, 32]. Imaging modality of 
choice to visualize deep CVT is MRI T1W1 [12]. Family 
history of coagulation disorders should raise suspicion 
for CVT for anyone presenting with neurological findings 
at HA. Nair et al demonstrated that PA1-1 
polymorphism lead to widespread thrombosis at 
multiple sites including aorta, bilateral iliac arteries, 
middle cerebral artery and CVT of superior sagittal sinus 
[7].
PROGNOSIS
 
The main determinant of prognosis is timely diagnosis 
and treatment. Hemorrhage is a common sequela of 
CVT and worsens clinical outcome [11]. Most cases of 
CVT show good recovery with a combination of quick 
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nature of diagnosis and treatment and the extent of the 
thrombosis. Bilateral or extensive thrombosis coupled 
with underlying coagulation disorder is associated with 
poor prognosis. Understanding the pathophysiology and 
the risk factors can help prevent incidence of CVT at 
high altitude as well as educate physicians and 
climbers about prompt diagnosis, treatment, screening 
and appropriate preventive measures. 
SEARCH METHODOLOGY
Comprehensive literature search was done on search 
engines PubMed and Google Scholar using the 
keywords “Cerebral Venous Thrombosis”, “High 
Altitude” and “Venous Thrombosis”. The following 
search query was used in PubMed: (“Cerebral Venous 
Thrombosis” [MeSh]) OR (Cerebral Venous 
Thrombosis[Title] AND High Altitude[Title]) OR (Cerebral 
Venous Thrombosis[Title] OR High Altitude) OR 
(Cerebral Venous Thrombosis at High Altitude[Title]). 
Inclusion criteria consisted of articles from journals that 
were PubMed indexed and published in the last 20 
years. A total of 40 articles were reviewed, out of which 
32 were included in the final paper. The references in 
papers found to be eligible were taken into account and 
screened for relevant information. The full text of all 
acceptable papers was accessed and read thoroughly. 
A comprehensive table of all pertinent information was 
made for easy access during article writing. Literature 
related to pathophysiology of venous thrombosis due to 
hypoxia was selected according to its relevance and 
recentness.
HIGH ALTITUDE (HA)
Barometric pressure decreases at an exponential rate 
as higher altitudes are reached, leading to a decrease 
in the partial pressure of Oxygen, which results in brain 
receiving less oxygen, hence inducing hypoxia [4]. CVT 
has been mostly described to occur between altitudes 
ranging from 2500m to 5500m [1]. It has been 
proposed that activation of coagulation factors leading 
to a prothrombotic state is rate dependent, i.e the 
more rapid the ascent to HA, higher the risk of 
developing CVT [5, 10].  Comparatively, gradual ascent 
to HA and well-acclimatized individuals pose a lesser 
risk of thrombosis. A study held in India compared 
1692 patient profiles comparing incidence of 
thrombosis in extremely HA (>5000m) and sea levels 
found that there was a 30 times higher incidence of 
CVT at HA [8]. Similarly, a study done on healthy, young 
soldiers at 3500m found a 30 times higher incidence 
of thrombosis [5].  Another study found that lowlanders 
posted at 3883m had 30-44 times increased 
incidence of deep vein thrombosis [6]. It was suggested 
that acute exposure to hypoxia solely cannot 
predispose to thrombosis without significant underlying 
shift in hemostasis [11]. There is a lack of good studies 
to determine the exact cause of hypercoagulability in 
HA especially since most of current studies in the West 
are performed in artificially simulated hypoxic 
environment. CVT can occur in lower than average 
altitude in people with pre-existing underlying 
prothrombotic state. Prolonged duration of stay is also 
associated with higher incidence of CVT as illustrated 
by various case reports. Table 1 shows incidents of CVT 
in high altitude.
TABLE 1: CASE REPORTS AND STUDIES WITH 
ASSOCIATED ALTITUDES AT WHICH CVT INCIDENCE 
OCCURRED.
AGE
At HA, CVT is typically observed in young to middle aged 
individuals [1]. Extremes of ages have also been 
reported with a 75-year-old man with an underlying 
case of hyperhomocysteinemia developing deep CVT at 
an altitude of 2200 m for 3 days [12] and a 
19-year-old female developing sinus vein thrombosis 
after a high altitude training of 2 months [10]. 
GENDER
There’s an evident gender disparity in the 
documentation of CVT at high altitude, with a 
significantly higher incidence of CVT in males [1]. Most 
of the stronger studies were done on stationed soldiers 
and male trekkers [2,3,5,6,7,8]. and majority of the 
case reports document male patients [11, 
12,15,16,17,18,19]. Mountaineering is a 
male-dominated sport [14]. Women have additional 
risk factors such as oral contraceptive pills and 
pregnancy that predisposes them to venous 
thrombosis. Reported cases of females developing CVT 
at HA always had an existing underlying risk factor. A 
young female developing sinus vein thrombosis at HA 
had a history of oral contraceptive use that she claimed 
to have stopped taken 3 years prior to the incident 
[10]. Similarly, Shrestha et al. reported another female 
with heterozygous mutation of Factor V Leiden and low 
plasma levels of protein S suffered from CVT at 5600m 
[13]. A 39-year-old female was reported to develop 
bilateral deep subcortical infarction in combination with 
Acute Mountain Sickness [9].
CONGENITAL THROMBOPHILIAS
A pre-existing prothrombotic state, such as congenital 
thrombophilias, appears to the most common risk 
factor for developing CVT in a HA setting. A systemic 
review showed 9 out of 14 reported cases had an 
underlying hypercoagulable state with secondary 
polycythemia and Factor V Leiden mutations being the 
most common [1]. Heterozygous Factor V Leiden 
mutation increases the risk of thromboembolism by 
seven fold, whereas homozygous mutation increases 
the risk by eight-fold [20]. Bolous et al reported a case 
of sudden onset of right sided hemiplegia and aphasia 
secondary to CVT at 3000m in a 42-year-old man with 
congenital protein C deficiency, while Nair et al shares 
a case of a patient with a Protein S levels of 36% 
(normally 70-123%) presenting with CVT coupled with 
DVT. Both cases were distinct for positive family history 
of hypercoagulability [17]. Grabe et al recorded a case 
of homonymous hemaniopia from deep CVT leading to 
infarction of the optic tract and lateral geniculate 
nucleus at 4800m with an underlying heterozygous 
Factor V Leiden mutation and elevated Factor VIII levels 
[18]. Nair et al reports a case of 35-year-old patient 
with both intra-arterial and venous thrombosis at 
multiple sites including the superior sagittal sinus with 
an increased Plasminogen Activator Inhibitor 1 (PAI-1) 
due to 4G/4G genotype polymorphism [7].  Hassan et 
al brings to attention a case of a rare association 
between protein S deficiency and 
hyperhomocysteinemia that resulted in severe deep 
CVT [12]. 
OTHER RISK FACTORS
Factors that predispose to CVT formation include 
infections, head trauma, malignancy and drugs with 
prothrombotic tendencies. On HA, additional risk 
factors to consider are dehydration, immobility, 
polycythemia and changes in hemostasis. Dehydration 
secondary to reduced water intake, increased physical 
exertion as well as vomiting and diarrhea due to AMS 
can predispose to increased hemoconcentration 
[9,13]. Hemoconcentration also increases due to 
eventual acclimatization which leads to polycythemia 
and increased blood viscosity. The process of 
acclimatization brings about numerous changes in 
blood physiology leading to a higher risk of thrombus 
formation. Whilst full acclimatization is achieved, 
hematocrit is believed to have increased by 50% [20]. 
Significant increase in hemoglobin levels, hematocrit 
and RBC count is reported in various studies done on 
HA [5, 6]. Increased blood viscosity increases mean 
PTT and causes endothelial damage leading to clot 
formation. Polycythemia also results in increased 
cerebral blood flow, subsequently increasing 
intracranial pressure which in turn disrupts the cerebral 
venous blood flow. Although most cases of CVT at HA 
are observed in lowlanders acutely exposed to high 
altitude conditions, a few cases have also been 
observed in well acclimatized individuals native to such 
conditions. A case of vein of Galen thrombosis was 
observed in a permanent citizen of the Tibetan plateau 
(4000m) with an additional risk factor of recent history 
of trauma (bilateral acetabular fracture), high blood 
pressure, history of smoking and hemoglobin of 191 
g/L [16]. Similar case of a well acclimatized man 
presenting with occlusion of superior sagittal and right 
transverse sinuses around his 45th day at 5000m 
altitude, with an additional risk factor of pre-existing 
brain sinus narrowing and anomalies [19]. 10%-30% of 
the population is believed to have structural brain sinus 
anomalies. Extreme cold can trigger coagulation 
cascade [23].
SUGGESTED MECHANISMS
The precise etiopathology of thrombosis at HA is 
obscure. The literature contains conflicting studies 
offering a wide array of plausible explanations regarding 
the underlying mechanisms that lead to a 
hypercoaguable state at HA. Hypoxia-induced 
customization of hemostasis and coagulation factors 
results in simultaneous changes in multiple 
components of blood, predisposing to thrombosis. 
ROLE OF INFLAMMATION
Gupta et al emphasized the presence of an active 
proinflammatory response to hypoxia employing innate 
and adaptive immune cells resulting in aggravated 
venous thrombosis. This proinflammatory state 
develops in response to HA due to the action of 
Hypoxia-induced factor 1-alpha (HIF-1a) on NLRP3 
gene expression leading to formation of NLRP3 
inflammasome [21]. This study documents the 
presence of NLRP3, caspase-1 and IL- β in individuals 
who formed venous thrombosis. Additionally, another 
contributing factor is believed to be 
endothelin-1-mediated and interleukin-6-mediated 
endothelial activation and related inflammatory 
response [15].  
  
ROLE OF FACTOR VIII, PAI-1 
AND PLATELET ACTIVITY
Kicken et al attributed the increase in thrombin levels 
mediated by increased Factor VIII levels to be the cause 
of increased hypercoagulability at HA. Factor VIII levels 
were presumed to be increased due to the oxidative 
stress in circulation due to tissue hypoxia, asserting 
that hypoxia alters the “redox status” of the blood [6]. 
This study also found that platelet aggregation was 
reduced at HA, attributing to increased ADP and 
epinephrine. Antithrombin levels, D-dimers and 
coagulation factors remained unchanged as compared 
to sea levels. Interestingly, subjects which were 
pretreated with Vitamin E had a reduced incidence of 
venous thrombosis [6]. On the other hand, Kotwal et al 
studied the effect of high altitude on hemostasis at 
induction, 3 months and 8 months and reported a 
significant rise in platelet count and platelet activation 
factors (BTG and PF4). This study also reported a 
significant rise in hemoglobin, PAI-1 activity and plasma 
fibrinogen, asserting a positive relationship between 
the latter two and postulating the significance of PAI-1 
in “tilting the balance” towards thrombosis by 
decreasing fibrinolytic activity. Kotwal et al also 
emphasized that platelet aggregation in the context of 
thrombosis was not a reliable method, instead BTG and 
PF4 measured on ELISA assay were more illustrative of 
platelet activity [5]. 
Martin et al contradicts aforementioned findings by 
analyzing the kinetics of clot formation using 
thromboelastography to study the effects of hypoxia at 
4250 m and 5300m on coagulation [3].  It was found 
that exposure to hypoxia decreases blood coagulability 
[3].
ROLE OF INCREASED SYMPATHETIC ACTIVITY
Hypoxia is also believed to trigger the body’s 
sympathetic response and increased sympathetic 
activity has a strong relationship with stroke [20, 22]. 
Constantly increased norepinephrine activates platelet 
hyperfunctioning leading to a hypercoagulable state 
[22]. 
Clinical Features and Diagnostic Challenges
There’s a considerable variation in the clinical features 
associated with CVT. Severity of the presentation is 
contingent with the extent of the thrombosis, sinuses 
involved and development of venous collaterals [12]. 
Most common signs and symptoms include 
headaches, focal neurological deficits, seizures and 
altered mental status [1, 2]. Other symptoms include 
papilledema and behavioral changes. Both cytotoxic 
and vasogenic cerebral edema are associated with CVT 
[28]. These present with an acute onset and the 
headaches are often associated with vomiting, 
confusion and loss of consciousness. Deep CVT 
involving the thalamus, basal ganglia and subcortical 
white matter presents as serious neurological 
emergency [12,16,18]. 
More common neurological conditions associated with 
high altitude are High-altitude headache (HAH), Acute 
mountain sickness (AMS) and High altitude cerebral 
edema (HACE). These render the accurate diagnosis 
difficult due to several overlapping clinical features. For 
example, HACE presents as altered mental status, 
ataxia of gait, and psychiatric changes that can lead to 
deep coma. Table 2 illustrates the clinical features of 
patients who developed CVT at HA. 
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anticoagulation and rehabilitation [29]. Failure to 
anticoagulated results in poor prognosis [9, 29]. 25% 
of patients with CVT deteriorate despite adequate 
anticoagulation [2]. Overall mortality rate associated 
with CVT is 34.2% [29]. Bilateral CVT (which male up 
3%-8% of all CVT) and deep CVT present with severe 
clinical features and are associated with poor clinical 
outcome [2,9,16,18]. According to the International 
Study of Cerebral Vein and Dural Thrombosis (ISCVT) 
13% had poor neurological outcome whereas 4.3% 
were recorded to have died during the acute phase. 
Bushnaq et al demonstrated that the most significant 
predictor of poor prognosis to be altered or decreased 
mental status. Other indicators for poor prognosis are 
seizures, papilledema, hyponatremia (<139mEq/L), 
low platelet count (<225x109/L) and involvement of 
more than one sinus [2]. Endovascular therapy has 
been used as a salvage intervention, however there’s 
not much evidence to support its efficiency in 
decreasing mortality. Delaying thrombectomy can result 
in fibrosing of the thrombus leading to permanent 
neurological damage [2].
TREATMENT
 
Treatment of choice for CVT at HA is anticoagulation 
with subcutaneous Low Molecular Weight Heparin [32]. 
In the acute phase of the disease, first concern should 
be to stabilize and prevent cerebral herniation [28]. 
Decompressive surgery is strongly suggested for acute 
CVT with parenchymal involvement [32]. Use of 
acetazolamide, steroids and thrombolysis in acute CVT 
is discouraged [32]. For medically-refractory cases, 
mechanical thrombectomy can be considered [31]. 
Long term anticoagulation with warfarin or newer oral 
anticoagulants (NOACs) may be required for variable 
periods.
PROPHYLAXIS
LMWH and Warfarin are proven to be acceptable 
prophylaxis against hypercoagulabity at HA.  Use of oral 
anticoagulants after an episode of CVT to prevent 
further incidence has low evidence of impact and not 
recommended [32].
Oral Contraceptive Pills should be discontinued by 
females before embarking on a HA journey.
FUTURE DIRECTIONS
The exact incidence and mortality rate of CVT on a HA 
is unknown. Almost all epidemiological studies about 
CVT are based on normal altitude, not taking in account 
the additional risk factors associated with hypobaric 
hypoxia. Most high altitude studies were done on male, 
middle-aged soldiers or mountaineers without proper 
controls, this gives rise to bias and inaccuracy. 
Multi-center academic collaborations between 
institutions investigating incidence of high 
altitude-associated CVT can help improve the current 
understanding about involved risk factors. A case 
control study will be useful in identifying risk factors for 
high altitude CVT. Future intervention trials could be 
planned targeting high risk populations. Determining 
the precise altitude at which the risk of developing CVT 
increases significantly can help caution susceptible 
individuals. Although screening for thrombophilias is 
not recommended for CVT at normal altitude [32], 
studies showing a strong relationship between the two 
should prompt further research on whether 
thrombophilia screening should be incorporated in the 
diagnostic protocol for CVT cases presenting at a HA 
setting. Those set to experience hypobaric hypoxic 
conditions should also get routine blood counts to 
screen for polycythemia and thrombocytosis. Screening 
for Vitamin B12 and Folate levels can help detect a 
state of hyperhomocysteinemia. Health care 
professionals should also be trained to consider and 
diagnose CVT in patients with neurological symptoms. 
Availability of imaging modalities such as CT and MRI 
scan can lead to quicker diagnosis and treatment. More 
research should be focused on the underlying 
pathophysiology and mechanisms involved with 
hypoxia-associated CVT to create effective prophylaxis, 
protocols and treatment plans.
CONCLUSION
 
Cerebral Venous Thrombosis occurring at high altitude 
is a neurological emergency that requires timely 
diagnosis and treatment. It has complex underlying 
mechanisms and etiologies as well as numerous 
clinical presentations.  Understanding the predisposing 
factors to this phenomenon can lead to effective 
preventive measures, quicker diagnosis and 
management. Individuals with history of coagulation 
abnormalities should be screened for underlying 
thrombophilias and cautiously ascend to higher 
altitudes. CVT should be considered in all neurological 
clinical presentations at high altitude. High altitude 
trekkers should be educated on how to keep hydrated 
and avoid immobility, exposure to extreme cold and 
seeking immediate help for symptoms like headache 
and disturbed mental status. Patients with no 
contraindications to anticoagulation should be 
immediately anticoagulated with appropriate drugs.
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DIAGNOSIS
Neuroimaging plays a vital role in the diagnosis and 
clinical outcome [31]. Two most common imaging 
modalities used to confirm diagnosis of CVT are CT scan 
and MRI, and MRV when not visualized in MRI [1, 32]. 
There are alterations in the intensity of the thrombus 
depending on its age [31]. Most common sinuses to be 
affected is the superior sagittal sinus and transverse 
sinus [1, 2]. Kim et al weren’t able to locate any 
indication of thrombosis except for vasogenic edema 
with a hemorrhagic component on MRI [15]. D-dimer 
level can be effective to diagnose restricted sinus 
involvement or in older individuals, however, there is a 
chance of false negative results and its role in diagnosis 
remains controversial [24, 32]. Imaging modality of 
choice to visualize deep CVT is MRI T1W1 [12]. Family 
history of coagulation disorders should raise suspicion 
for CVT for anyone presenting with neurological findings 
at HA. Nair et al demonstrated that PA1-1 
polymorphism lead to widespread thrombosis at 
multiple sites including aorta, bilateral iliac arteries, 
middle cerebral artery and CVT of superior sagittal sinus 
[7].
PROGNOSIS
 
The main determinant of prognosis is timely diagnosis 
and treatment. Hemorrhage is a common sequela of 
CVT and worsens clinical outcome [11]. Most cases of 
CVT show good recovery with a combination of quick 
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nature of diagnosis and treatment and the extent of the 
thrombosis. Bilateral or extensive thrombosis coupled 
with underlying coagulation disorder is associated with 
poor prognosis. Understanding the pathophysiology and 
the risk factors can help prevent incidence of CVT at 
high altitude as well as educate physicians and 
climbers about prompt diagnosis, treatment, screening 
and appropriate preventive measures. 
SEARCH METHODOLOGY
Comprehensive literature search was done on search 
engines PubMed and Google Scholar using the 
keywords “Cerebral Venous Thrombosis”, “High 
Altitude” and “Venous Thrombosis”. The following 
search query was used in PubMed: (“Cerebral Venous 
Thrombosis” [MeSh]) OR (Cerebral Venous 
Thrombosis[Title] AND High Altitude[Title]) OR (Cerebral 
Venous Thrombosis[Title] OR High Altitude) OR 
(Cerebral Venous Thrombosis at High Altitude[Title]). 
Inclusion criteria consisted of articles from journals that 
were PubMed indexed and published in the last 20 
years. A total of 40 articles were reviewed, out of which 
32 were included in the final paper. The references in 
papers found to be eligible were taken into account and 
screened for relevant information. The full text of all 
acceptable papers was accessed and read thoroughly. 
A comprehensive table of all pertinent information was 
made for easy access during article writing. Literature 
related to pathophysiology of venous thrombosis due to 
hypoxia was selected according to its relevance and 
recentness.
HIGH ALTITUDE (HA)
Barometric pressure decreases at an exponential rate 
as higher altitudes are reached, leading to a decrease 
in the partial pressure of Oxygen, which results in brain 
receiving less oxygen, hence inducing hypoxia [4]. CVT 
has been mostly described to occur between altitudes 
ranging from 2500m to 5500m [1]. It has been 
proposed that activation of coagulation factors leading 
to a prothrombotic state is rate dependent, i.e the 
more rapid the ascent to HA, higher the risk of 
developing CVT [5, 10].  Comparatively, gradual ascent 
to HA and well-acclimatized individuals pose a lesser 
risk of thrombosis. A study held in India compared 
1692 patient profiles comparing incidence of 
thrombosis in extremely HA (>5000m) and sea levels 
found that there was a 30 times higher incidence of 
CVT at HA [8]. Similarly, a study done on healthy, young 
soldiers at 3500m found a 30 times higher incidence 
of thrombosis [5].  Another study found that lowlanders 
posted at 3883m had 30-44 times increased 
incidence of deep vein thrombosis [6]. It was suggested 
that acute exposure to hypoxia solely cannot 
predispose to thrombosis without significant underlying 
shift in hemostasis [11]. There is a lack of good studies 
to determine the exact cause of hypercoagulability in 
HA especially since most of current studies in the West 
are performed in artificially simulated hypoxic 
environment. CVT can occur in lower than average 
altitude in people with pre-existing underlying 
prothrombotic state. Prolonged duration of stay is also 
associated with higher incidence of CVT as illustrated 
by various case reports. Table 1 shows incidents of CVT 
in high altitude.
TABLE 1: CASE REPORTS AND STUDIES WITH 
ASSOCIATED ALTITUDES AT WHICH CVT INCIDENCE 
OCCURRED.
AGE
At HA, CVT is typically observed in young to middle aged 
individuals [1]. Extremes of ages have also been 
reported with a 75-year-old man with an underlying 
case of hyperhomocysteinemia developing deep CVT at 
an altitude of 2200 m for 3 days [12] and a 
19-year-old female developing sinus vein thrombosis 
after a high altitude training of 2 months [10]. 
GENDER
There’s an evident gender disparity in the 
documentation of CVT at high altitude, with a 
significantly higher incidence of CVT in males [1]. Most 
of the stronger studies were done on stationed soldiers 
and male trekkers [2,3,5,6,7,8]. and majority of the 
case reports document male patients [11, 
12,15,16,17,18,19]. Mountaineering is a 
male-dominated sport [14]. Women have additional 
risk factors such as oral contraceptive pills and 
pregnancy that predisposes them to venous 
thrombosis. Reported cases of females developing CVT 
at HA always had an existing underlying risk factor. A 
young female developing sinus vein thrombosis at HA 
had a history of oral contraceptive use that she claimed 
to have stopped taken 3 years prior to the incident 
[10]. Similarly, Shrestha et al. reported another female 
with heterozygous mutation of Factor V Leiden and low 
plasma levels of protein S suffered from CVT at 5600m 
[13]. A 39-year-old female was reported to develop 
bilateral deep subcortical infarction in combination with 
Acute Mountain Sickness [9].
CONGENITAL THROMBOPHILIAS
A pre-existing prothrombotic state, such as congenital 
thrombophilias, appears to the most common risk 
factor for developing CVT in a HA setting. A systemic 
review showed 9 out of 14 reported cases had an 
underlying hypercoagulable state with secondary 
polycythemia and Factor V Leiden mutations being the 
most common [1]. Heterozygous Factor V Leiden 
mutation increases the risk of thromboembolism by 
seven fold, whereas homozygous mutation increases 
the risk by eight-fold [20]. Bolous et al reported a case 
of sudden onset of right sided hemiplegia and aphasia 
secondary to CVT at 3000m in a 42-year-old man with 
congenital protein C deficiency, while Nair et al shares 
a case of a patient with a Protein S levels of 36% 
(normally 70-123%) presenting with CVT coupled with 
DVT. Both cases were distinct for positive family history 
of hypercoagulability [17]. Grabe et al recorded a case 
of homonymous hemaniopia from deep CVT leading to 
infarction of the optic tract and lateral geniculate 
nucleus at 4800m with an underlying heterozygous 
Factor V Leiden mutation and elevated Factor VIII levels 
[18]. Nair et al reports a case of 35-year-old patient 
with both intra-arterial and venous thrombosis at 
multiple sites including the superior sagittal sinus with 
an increased Plasminogen Activator Inhibitor 1 (PAI-1) 
due to 4G/4G genotype polymorphism [7].  Hassan et 
al brings to attention a case of a rare association 
between protein S deficiency and 
hyperhomocysteinemia that resulted in severe deep 
CVT [12]. 
OTHER RISK FACTORS
Factors that predispose to CVT formation include 
infections, head trauma, malignancy and drugs with 
prothrombotic tendencies. On HA, additional risk 
factors to consider are dehydration, immobility, 
polycythemia and changes in hemostasis. Dehydration 
secondary to reduced water intake, increased physical 
exertion as well as vomiting and diarrhea due to AMS 
can predispose to increased hemoconcentration 
[9,13]. Hemoconcentration also increases due to 
eventual acclimatization which leads to polycythemia 
and increased blood viscosity. The process of 
acclimatization brings about numerous changes in 
blood physiology leading to a higher risk of thrombus 
formation. Whilst full acclimatization is achieved, 
hematocrit is believed to have increased by 50% [20]. 
Significant increase in hemoglobin levels, hematocrit 
and RBC count is reported in various studies done on 
HA [5, 6]. Increased blood viscosity increases mean 
PTT and causes endothelial damage leading to clot 
formation. Polycythemia also results in increased 
cerebral blood flow, subsequently increasing 
intracranial pressure which in turn disrupts the cerebral 
venous blood flow. Although most cases of CVT at HA 
are observed in lowlanders acutely exposed to high 
altitude conditions, a few cases have also been 
observed in well acclimatized individuals native to such 
conditions. A case of vein of Galen thrombosis was 
observed in a permanent citizen of the Tibetan plateau 
(4000m) with an additional risk factor of recent history 
of trauma (bilateral acetabular fracture), high blood 
pressure, history of smoking and hemoglobin of 191 
g/L [16]. Similar case of a well acclimatized man 
presenting with occlusion of superior sagittal and right 
transverse sinuses around his 45th day at 5000m 
altitude, with an additional risk factor of pre-existing 
brain sinus narrowing and anomalies [19]. 10%-30% of 
the population is believed to have structural brain sinus 
anomalies. Extreme cold can trigger coagulation 
cascade [23].
SUGGESTED MECHANISMS
The precise etiopathology of thrombosis at HA is 
obscure. The literature contains conflicting studies 
offering a wide array of plausible explanations regarding 
the underlying mechanisms that lead to a 
hypercoaguable state at HA. Hypoxia-induced 
customization of hemostasis and coagulation factors 
results in simultaneous changes in multiple 
components of blood, predisposing to thrombosis. 
ROLE OF INFLAMMATION
Gupta et al emphasized the presence of an active 
proinflammatory response to hypoxia employing innate 
and adaptive immune cells resulting in aggravated 
venous thrombosis. This proinflammatory state 
develops in response to HA due to the action of 
Hypoxia-induced factor 1-alpha (HIF-1a) on NLRP3 
gene expression leading to formation of NLRP3 
inflammasome [21]. This study documents the 
presence of NLRP3, caspase-1 and IL- β in individuals 
who formed venous thrombosis. Additionally, another 
contributing factor is believed to be 
endothelin-1-mediated and interleukin-6-mediated 
endothelial activation and related inflammatory 
response [15].  
  
ROLE OF FACTOR VIII, PAI-1 
AND PLATELET ACTIVITY
Kicken et al attributed the increase in thrombin levels 
mediated by increased Factor VIII levels to be the cause 
of increased hypercoagulability at HA. Factor VIII levels 
were presumed to be increased due to the oxidative 
stress in circulation due to tissue hypoxia, asserting 
that hypoxia alters the “redox status” of the blood [6]. 
This study also found that platelet aggregation was 
reduced at HA, attributing to increased ADP and 
epinephrine. Antithrombin levels, D-dimers and 
coagulation factors remained unchanged as compared 
to sea levels. Interestingly, subjects which were 
pretreated with Vitamin E had a reduced incidence of 
venous thrombosis [6]. On the other hand, Kotwal et al 
studied the effect of high altitude on hemostasis at 
induction, 3 months and 8 months and reported a 
significant rise in platelet count and platelet activation 
factors (BTG and PF4). This study also reported a 
significant rise in hemoglobin, PAI-1 activity and plasma 
fibrinogen, asserting a positive relationship between 
the latter two and postulating the significance of PAI-1 
in “tilting the balance” towards thrombosis by 
decreasing fibrinolytic activity. Kotwal et al also 
emphasized that platelet aggregation in the context of 
thrombosis was not a reliable method, instead BTG and 
PF4 measured on ELISA assay were more illustrative of 
platelet activity [5]. 
Martin et al contradicts aforementioned findings by 
analyzing the kinetics of clot formation using 
thromboelastography to study the effects of hypoxia at 
4250 m and 5300m on coagulation [3].  It was found 
that exposure to hypoxia decreases blood coagulability 
[3].
ROLE OF INCREASED SYMPATHETIC ACTIVITY
Hypoxia is also believed to trigger the body’s 
sympathetic response and increased sympathetic 
activity has a strong relationship with stroke [20, 22]. 
Constantly increased norepinephrine activates platelet 
hyperfunctioning leading to a hypercoagulable state 
[22]. 
Clinical Features and Diagnostic Challenges
There’s a considerable variation in the clinical features 
associated with CVT. Severity of the presentation is 
contingent with the extent of the thrombosis, sinuses 
involved and development of venous collaterals [12]. 
Most common signs and symptoms include 
headaches, focal neurological deficits, seizures and 
altered mental status [1, 2]. Other symptoms include 
papilledema and behavioral changes. Both cytotoxic 
and vasogenic cerebral edema are associated with CVT 
[28]. These present with an acute onset and the 
headaches are often associated with vomiting, 
confusion and loss of consciousness. Deep CVT 
involving the thalamus, basal ganglia and subcortical 
white matter presents as serious neurological 
emergency [12,16,18]. 
More common neurological conditions associated with 
high altitude are High-altitude headache (HAH), Acute 
mountain sickness (AMS) and High altitude cerebral 
edema (HACE). These render the accurate diagnosis 
difficult due to several overlapping clinical features. For 
example, HACE presents as altered mental status, 
ataxia of gait, and psychiatric changes that can lead to 
deep coma. Table 2 illustrates the clinical features of 
patients who developed CVT at HA. 
anticoagulation and rehabilitation [29]. Failure to 
anticoagulated results in poor prognosis [9, 29]. 25% 
of patients with CVT deteriorate despite adequate 
anticoagulation [2]. Overall mortality rate associated 
with CVT is 34.2% [29]. Bilateral CVT (which male up 
3%-8% of all CVT) and deep CVT present with severe 
clinical features and are associated with poor clinical 
outcome [2,9,16,18]. According to the International 
Study of Cerebral Vein and Dural Thrombosis (ISCVT) 
13% had poor neurological outcome whereas 4.3% 
were recorded to have died during the acute phase. 
Bushnaq et al demonstrated that the most significant 
predictor of poor prognosis to be altered or decreased 
mental status. Other indicators for poor prognosis are 
seizures, papilledema, hyponatremia (<139mEq/L), 
low platelet count (<225x109/L) and involvement of 
more than one sinus [2]. Endovascular therapy has 
been used as a salvage intervention, however there’s 
not much evidence to support its efficiency in 
decreasing mortality. Delaying thrombectomy can result 
in fibrosing of the thrombus leading to permanent 
neurological damage [2].
TREATMENT
 
Treatment of choice for CVT at HA is anticoagulation 
with subcutaneous Low Molecular Weight Heparin [32]. 
In the acute phase of the disease, first concern should 
be to stabilize and prevent cerebral herniation [28]. 
Decompressive surgery is strongly suggested for acute 
CVT with parenchymal involvement [32]. Use of 
acetazolamide, steroids and thrombolysis in acute CVT 
is discouraged [32]. For medically-refractory cases, 
mechanical thrombectomy can be considered [31]. 
Long term anticoagulation with warfarin or newer oral 
anticoagulants (NOACs) may be required for variable 
periods.
PROPHYLAXIS
LMWH and Warfarin are proven to be acceptable 
prophylaxis against hypercoagulabity at HA.  Use of oral 
anticoagulants after an episode of CVT to prevent 
further incidence has low evidence of impact and not 
recommended [32].
Oral Contraceptive Pills should be discontinued by 
females before embarking on a HA journey.
FUTURE DIRECTIONS
The exact incidence and mortality rate of CVT on a HA 
is unknown. Almost all epidemiological studies about 
CVT are based on normal altitude, not taking in account 
the additional risk factors associated with hypobaric 
hypoxia. Most high altitude studies were done on male, 
middle-aged soldiers or mountaineers without proper 
controls, this gives rise to bias and inaccuracy. 
Multi-center academic collaborations between 
institutions investigating incidence of high 
altitude-associated CVT can help improve the current 
understanding about involved risk factors. A case 
control study will be useful in identifying risk factors for 
high altitude CVT. Future intervention trials could be 
planned targeting high risk populations. Determining 
the precise altitude at which the risk of developing CVT 
increases significantly can help caution susceptible 
individuals. Although screening for thrombophilias is 
not recommended for CVT at normal altitude [32], 
studies showing a strong relationship between the two 
should prompt further research on whether 
thrombophilia screening should be incorporated in the 
diagnostic protocol for CVT cases presenting at a HA 
setting. Those set to experience hypobaric hypoxic 
conditions should also get routine blood counts to 
screen for polycythemia and thrombocytosis. Screening 
for Vitamin B12 and Folate levels can help detect a 
state of hyperhomocysteinemia. Health care 
professionals should also be trained to consider and 
diagnose CVT in patients with neurological symptoms. 
Availability of imaging modalities such as CT and MRI 
scan can lead to quicker diagnosis and treatment. More 
research should be focused on the underlying 
pathophysiology and mechanisms involved with 
hypoxia-associated CVT to create effective prophylaxis, 
protocols and treatment plans.
CONCLUSION
 
Cerebral Venous Thrombosis occurring at high altitude 
is a neurological emergency that requires timely 
diagnosis and treatment. It has complex underlying 
mechanisms and etiologies as well as numerous 
clinical presentations.  Understanding the predisposing 
factors to this phenomenon can lead to effective 
preventive measures, quicker diagnosis and 
management. Individuals with history of coagulation 
abnormalities should be screened for underlying 
thrombophilias and cautiously ascend to higher 
altitudes. CVT should be considered in all neurological 
clinical presentations at high altitude. High altitude 
trekkers should be educated on how to keep hydrated 
and avoid immobility, exposure to extreme cold and 
seeking immediate help for symptoms like headache 
and disturbed mental status. Patients with no 
contraindications to anticoagulation should be 
immediately anticoagulated with appropriate drugs.
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DIAGNOSIS
Neuroimaging plays a vital role in the diagnosis and 
clinical outcome [31]. Two most common imaging 
modalities used to confirm diagnosis of CVT are CT scan 
and MRI, and MRV when not visualized in MRI [1, 32]. 
There are alterations in the intensity of the thrombus 
depending on its age [31]. Most common sinuses to be 
affected is the superior sagittal sinus and transverse 
sinus [1, 2]. Kim et al weren’t able to locate any 
indication of thrombosis except for vasogenic edema 
with a hemorrhagic component on MRI [15]. D-dimer 
level can be effective to diagnose restricted sinus 
involvement or in older individuals, however, there is a 
chance of false negative results and its role in diagnosis 
remains controversial [24, 32]. Imaging modality of 
choice to visualize deep CVT is MRI T1W1 [12]. Family 
history of coagulation disorders should raise suspicion 
for CVT for anyone presenting with neurological findings 
at HA. Nair et al demonstrated that PA1-1 
polymorphism lead to widespread thrombosis at 
multiple sites including aorta, bilateral iliac arteries, 
middle cerebral artery and CVT of superior sagittal sinus 
[7].
PROGNOSIS
 
The main determinant of prognosis is timely diagnosis 
and treatment. Hemorrhage is a common sequela of 
CVT and worsens clinical outcome [11]. Most cases of 
CVT show good recovery with a combination of quick 
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nature of diagnosis and treatment and the extent of the 
thrombosis. Bilateral or extensive thrombosis coupled 
with underlying coagulation disorder is associated with 
poor prognosis. Understanding the pathophysiology and 
the risk factors can help prevent incidence of CVT at 
high altitude as well as educate physicians and 
climbers about prompt diagnosis, treatment, screening 
and appropriate preventive measures. 
SEARCH METHODOLOGY
Comprehensive literature search was done on search 
engines PubMed and Google Scholar using the 
keywords “Cerebral Venous Thrombosis”, “High 
Altitude” and “Venous Thrombosis”. The following 
search query was used in PubMed: (“Cerebral Venous 
Thrombosis” [MeSh]) OR (Cerebral Venous 
Thrombosis[Title] AND High Altitude[Title]) OR (Cerebral 
Venous Thrombosis[Title] OR High Altitude) OR 
(Cerebral Venous Thrombosis at High Altitude[Title]). 
Inclusion criteria consisted of articles from journals that 
were PubMed indexed and published in the last 20 
years. A total of 40 articles were reviewed, out of which 
32 were included in the final paper. The references in 
papers found to be eligible were taken into account and 
screened for relevant information. The full text of all 
acceptable papers was accessed and read thoroughly. 
A comprehensive table of all pertinent information was 
made for easy access during article writing. Literature 
related to pathophysiology of venous thrombosis due to 
hypoxia was selected according to its relevance and 
recentness.
HIGH ALTITUDE (HA)
Barometric pressure decreases at an exponential rate 
as higher altitudes are reached, leading to a decrease 
in the partial pressure of Oxygen, which results in brain 
receiving less oxygen, hence inducing hypoxia [4]. CVT 
has been mostly described to occur between altitudes 
ranging from 2500m to 5500m [1]. It has been 
proposed that activation of coagulation factors leading 
to a prothrombotic state is rate dependent, i.e the 
more rapid the ascent to HA, higher the risk of 
developing CVT [5, 10].  Comparatively, gradual ascent 
to HA and well-acclimatized individuals pose a lesser 
risk of thrombosis. A study held in India compared 
1692 patient profiles comparing incidence of 
thrombosis in extremely HA (>5000m) and sea levels 
found that there was a 30 times higher incidence of 
CVT at HA [8]. Similarly, a study done on healthy, young 
soldiers at 3500m found a 30 times higher incidence 
of thrombosis [5].  Another study found that lowlanders 
posted at 3883m had 30-44 times increased 
incidence of deep vein thrombosis [6]. It was suggested 
that acute exposure to hypoxia solely cannot 
predispose to thrombosis without significant underlying 
shift in hemostasis [11]. There is a lack of good studies 
to determine the exact cause of hypercoagulability in 
HA especially since most of current studies in the West 
are performed in artificially simulated hypoxic 
environment. CVT can occur in lower than average 
altitude in people with pre-existing underlying 
prothrombotic state. Prolonged duration of stay is also 
associated with higher incidence of CVT as illustrated 
by various case reports. Table 1 shows incidents of CVT 
in high altitude.
TABLE 1: CASE REPORTS AND STUDIES WITH 
ASSOCIATED ALTITUDES AT WHICH CVT INCIDENCE 
OCCURRED.
AGE
At HA, CVT is typically observed in young to middle aged 
individuals [1]. Extremes of ages have also been 
reported with a 75-year-old man with an underlying 
case of hyperhomocysteinemia developing deep CVT at 
an altitude of 2200 m for 3 days [12] and a 
19-year-old female developing sinus vein thrombosis 
after a high altitude training of 2 months [10]. 
GENDER
There’s an evident gender disparity in the 
documentation of CVT at high altitude, with a 
significantly higher incidence of CVT in males [1]. Most 
of the stronger studies were done on stationed soldiers 
and male trekkers [2,3,5,6,7,8]. and majority of the 
case reports document male patients [11, 
12,15,16,17,18,19]. Mountaineering is a 
male-dominated sport [14]. Women have additional 
risk factors such as oral contraceptive pills and 
pregnancy that predisposes them to venous 
thrombosis. Reported cases of females developing CVT 
at HA always had an existing underlying risk factor. A 
young female developing sinus vein thrombosis at HA 
had a history of oral contraceptive use that she claimed 
to have stopped taken 3 years prior to the incident 
[10]. Similarly, Shrestha et al. reported another female 
with heterozygous mutation of Factor V Leiden and low 
plasma levels of protein S suffered from CVT at 5600m 
[13]. A 39-year-old female was reported to develop 
bilateral deep subcortical infarction in combination with 
Acute Mountain Sickness [9].
CONGENITAL THROMBOPHILIAS
A pre-existing prothrombotic state, such as congenital 
thrombophilias, appears to the most common risk 
factor for developing CVT in a HA setting. A systemic 
review showed 9 out of 14 reported cases had an 
underlying hypercoagulable state with secondary 
polycythemia and Factor V Leiden mutations being the 
most common [1]. Heterozygous Factor V Leiden 
mutation increases the risk of thromboembolism by 
seven fold, whereas homozygous mutation increases 
the risk by eight-fold [20]. Bolous et al reported a case 
of sudden onset of right sided hemiplegia and aphasia 
secondary to CVT at 3000m in a 42-year-old man with 
congenital protein C deficiency, while Nair et al shares 
a case of a patient with a Protein S levels of 36% 
(normally 70-123%) presenting with CVT coupled with 
DVT. Both cases were distinct for positive family history 
of hypercoagulability [17]. Grabe et al recorded a case 
of homonymous hemaniopia from deep CVT leading to 
infarction of the optic tract and lateral geniculate 
nucleus at 4800m with an underlying heterozygous 
Factor V Leiden mutation and elevated Factor VIII levels 
[18]. Nair et al reports a case of 35-year-old patient 
with both intra-arterial and venous thrombosis at 
multiple sites including the superior sagittal sinus with 
an increased Plasminogen Activator Inhibitor 1 (PAI-1) 
due to 4G/4G genotype polymorphism [7].  Hassan et 
al brings to attention a case of a rare association 
between protein S deficiency and 
hyperhomocysteinemia that resulted in severe deep 
CVT [12]. 
OTHER RISK FACTORS
Factors that predispose to CVT formation include 
infections, head trauma, malignancy and drugs with 
prothrombotic tendencies. On HA, additional risk 
factors to consider are dehydration, immobility, 
polycythemia and changes in hemostasis. Dehydration 
secondary to reduced water intake, increased physical 
exertion as well as vomiting and diarrhea due to AMS 
can predispose to increased hemoconcentration 
[9,13]. Hemoconcentration also increases due to 
eventual acclimatization which leads to polycythemia 
and increased blood viscosity. The process of 
acclimatization brings about numerous changes in 
blood physiology leading to a higher risk of thrombus 
formation. Whilst full acclimatization is achieved, 
hematocrit is believed to have increased by 50% [20]. 
Significant increase in hemoglobin levels, hematocrit 
and RBC count is reported in various studies done on 
HA [5, 6]. Increased blood viscosity increases mean 
PTT and causes endothelial damage leading to clot 
formation. Polycythemia also results in increased 
cerebral blood flow, subsequently increasing 
intracranial pressure which in turn disrupts the cerebral 
venous blood flow. Although most cases of CVT at HA 
are observed in lowlanders acutely exposed to high 
altitude conditions, a few cases have also been 
observed in well acclimatized individuals native to such 
conditions. A case of vein of Galen thrombosis was 
observed in a permanent citizen of the Tibetan plateau 
(4000m) with an additional risk factor of recent history 
of trauma (bilateral acetabular fracture), high blood 
pressure, history of smoking and hemoglobin of 191 
g/L [16]. Similar case of a well acclimatized man 
presenting with occlusion of superior sagittal and right 
transverse sinuses around his 45th day at 5000m 
altitude, with an additional risk factor of pre-existing 
brain sinus narrowing and anomalies [19]. 10%-30% of 
the population is believed to have structural brain sinus 
anomalies. Extreme cold can trigger coagulation 
cascade [23].
SUGGESTED MECHANISMS
The precise etiopathology of thrombosis at HA is 
obscure. The literature contains conflicting studies 
offering a wide array of plausible explanations regarding 
the underlying mechanisms that lead to a 
hypercoaguable state at HA. Hypoxia-induced 
customization of hemostasis and coagulation factors 
results in simultaneous changes in multiple 
components of blood, predisposing to thrombosis. 
ROLE OF INFLAMMATION
Gupta et al emphasized the presence of an active 
proinflammatory response to hypoxia employing innate 
and adaptive immune cells resulting in aggravated 
venous thrombosis. This proinflammatory state 
develops in response to HA due to the action of 
Hypoxia-induced factor 1-alpha (HIF-1a) on NLRP3 
gene expression leading to formation of NLRP3 
inflammasome [21]. This study documents the 
presence of NLRP3, caspase-1 and IL- β in individuals 
who formed venous thrombosis. Additionally, another 
contributing factor is believed to be 
endothelin-1-mediated and interleukin-6-mediated 
endothelial activation and related inflammatory 
response [15].  
  
ROLE OF FACTOR VIII, PAI-1 
AND PLATELET ACTIVITY
Kicken et al attributed the increase in thrombin levels 
mediated by increased Factor VIII levels to be the cause 
of increased hypercoagulability at HA. Factor VIII levels 
were presumed to be increased due to the oxidative 
stress in circulation due to tissue hypoxia, asserting 
that hypoxia alters the “redox status” of the blood [6]. 
This study also found that platelet aggregation was 
reduced at HA, attributing to increased ADP and 
epinephrine. Antithrombin levels, D-dimers and 
coagulation factors remained unchanged as compared 
to sea levels. Interestingly, subjects which were 
pretreated with Vitamin E had a reduced incidence of 
venous thrombosis [6]. On the other hand, Kotwal et al 
studied the effect of high altitude on hemostasis at 
induction, 3 months and 8 months and reported a 
significant rise in platelet count and platelet activation 
factors (BTG and PF4). This study also reported a 
significant rise in hemoglobin, PAI-1 activity and plasma 
fibrinogen, asserting a positive relationship between 
the latter two and postulating the significance of PAI-1 
in “tilting the balance” towards thrombosis by 
decreasing fibrinolytic activity. Kotwal et al also 
emphasized that platelet aggregation in the context of 
thrombosis was not a reliable method, instead BTG and 
PF4 measured on ELISA assay were more illustrative of 
platelet activity [5]. 
Martin et al contradicts aforementioned findings by 
analyzing the kinetics of clot formation using 
thromboelastography to study the effects of hypoxia at 
4250 m and 5300m on coagulation [3].  It was found 
that exposure to hypoxia decreases blood coagulability 
[3].
ROLE OF INCREASED SYMPATHETIC ACTIVITY
Hypoxia is also believed to trigger the body’s 
sympathetic response and increased sympathetic 
activity has a strong relationship with stroke [20, 22]. 
Constantly increased norepinephrine activates platelet 
hyperfunctioning leading to a hypercoagulable state 
[22]. 
Clinical Features and Diagnostic Challenges
There’s a considerable variation in the clinical features 
associated with CVT. Severity of the presentation is 
contingent with the extent of the thrombosis, sinuses 
involved and development of venous collaterals [12]. 
Most common signs and symptoms include 
headaches, focal neurological deficits, seizures and 
altered mental status [1, 2]. Other symptoms include 
papilledema and behavioral changes. Both cytotoxic 
and vasogenic cerebral edema are associated with CVT 
[28]. These present with an acute onset and the 
headaches are often associated with vomiting, 
confusion and loss of consciousness. Deep CVT 
involving the thalamus, basal ganglia and subcortical 
white matter presents as serious neurological 
emergency [12,16,18]. 
More common neurological conditions associated with 
high altitude are High-altitude headache (HAH), Acute 
mountain sickness (AMS) and High altitude cerebral 
edema (HACE). These render the accurate diagnosis 
difficult due to several overlapping clinical features. For 
example, HACE presents as altered mental status, 
ataxia of gait, and psychiatric changes that can lead to 
deep coma. Table 2 illustrates the clinical features of 
patients who developed CVT at HA. 
anticoagulation and rehabilitation [29]. Failure to 
anticoagulated results in poor prognosis [9, 29]. 25% 
of patients with CVT deteriorate despite adequate 
anticoagulation [2]. Overall mortality rate associated 
with CVT is 34.2% [29]. Bilateral CVT (which male up 
3%-8% of all CVT) and deep CVT present with severe 
clinical features and are associated with poor clinical 
outcome [2,9,16,18]. According to the International 
Study of Cerebral Vein and Dural Thrombosis (ISCVT) 
13% had poor neurological outcome whereas 4.3% 
were recorded to have died during the acute phase. 
Bushnaq et al demonstrated that the most significant 
predictor of poor prognosis to be altered or decreased 
mental status. Other indicators for poor prognosis are 
seizures, papilledema, hyponatremia (<139mEq/L), 
low platelet count (<225x109/L) and involvement of 
more than one sinus [2]. Endovascular therapy has 
been used as a salvage intervention, however there’s 
not much evidence to support its efficiency in 
decreasing mortality. Delaying thrombectomy can result 
in fibrosing of the thrombus leading to permanent 
neurological damage [2].
TREATMENT
 
Treatment of choice for CVT at HA is anticoagulation 
with subcutaneous Low Molecular Weight Heparin [32]. 
In the acute phase of the disease, first concern should 
be to stabilize and prevent cerebral herniation [28]. 
Decompressive surgery is strongly suggested for acute 
CVT with parenchymal involvement [32]. Use of 
acetazolamide, steroids and thrombolysis in acute CVT 
is discouraged [32]. For medically-refractory cases, 
mechanical thrombectomy can be considered [31]. 
Long term anticoagulation with warfarin or newer oral 
anticoagulants (NOACs) may be required for variable 
periods.
PROPHYLAXIS
LMWH and Warfarin are proven to be acceptable 
prophylaxis against hypercoagulabity at HA.  Use of oral 
anticoagulants after an episode of CVT to prevent 
further incidence has low evidence of impact and not 
recommended [32].
Oral Contraceptive Pills should be discontinued by 
females before embarking on a HA journey.
FUTURE DIRECTIONS
The exact incidence and mortality rate of CVT on a HA 
is unknown. Almost all epidemiological studies about 
CVT are based on normal altitude, not taking in account 
the additional risk factors associated with hypobaric 
hypoxia. Most high altitude studies were done on male, 
middle-aged soldiers or mountaineers without proper 
controls, this gives rise to bias and inaccuracy. 
Multi-center academic collaborations between 
institutions investigating incidence of high 
altitude-associated CVT can help improve the current 
understanding about involved risk factors. A case 
control study will be useful in identifying risk factors for 
high altitude CVT. Future intervention trials could be 
planned targeting high risk populations. Determining 
the precise altitude at which the risk of developing CVT 
increases significantly can help caution susceptible 
individuals. Although screening for thrombophilias is 
not recommended for CVT at normal altitude [32], 
studies showing a strong relationship between the two 
should prompt further research on whether 
thrombophilia screening should be incorporated in the 
diagnostic protocol for CVT cases presenting at a HA 
setting. Those set to experience hypobaric hypoxic 
conditions should also get routine blood counts to 
screen for polycythemia and thrombocytosis. Screening 
for Vitamin B12 and Folate levels can help detect a 
state of hyperhomocysteinemia. Health care 
professionals should also be trained to consider and 
diagnose CVT in patients with neurological symptoms. 
Availability of imaging modalities such as CT and MRI 
scan can lead to quicker diagnosis and treatment. More 
research should be focused on the underlying 
pathophysiology and mechanisms involved with 
hypoxia-associated CVT to create effective prophylaxis, 
protocols and treatment plans.
CONCLUSION
 
Cerebral Venous Thrombosis occurring at high altitude 
is a neurological emergency that requires timely 
diagnosis and treatment. It has complex underlying 
mechanisms and etiologies as well as numerous 
clinical presentations.  Understanding the predisposing 
factors to this phenomenon can lead to effective 
preventive measures, quicker diagnosis and 
management. Individuals with history of coagulation 
abnormalities should be screened for underlying 
thrombophilias and cautiously ascend to higher 
altitudes. CVT should be considered in all neurological 
clinical presentations at high altitude. High altitude 
trekkers should be educated on how to keep hydrated 
and avoid immobility, exposure to extreme cold and 
seeking immediate help for symptoms like headache 
and disturbed mental status. Patients with no 
contraindications to anticoagulation should be 
immediately anticoagulated with appropriate drugs.
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DIAGNOSIS
Neuroimaging plays a vital role in the diagnosis and 
clinical outcome [31]. Two most common imaging 
modalities used to confirm diagnosis of CVT are CT scan 
and MRI, and MRV when not visualized in MRI [1, 32]. 
There are alterations in the intensity of the thrombus 
depending on its age [31]. Most common sinuses to be 
affected is the superior sagittal sinus and transverse 
sinus [1, 2]. Kim et al weren’t able to locate any 
indication of thrombosis except for vasogenic edema 
with a hemorrhagic component on MRI [15]. D-dimer 
level can be effective to diagnose restricted sinus 
involvement or in older individuals, however, there is a 
chance of false negative results and its role in diagnosis 
remains controversial [24, 32]. Imaging modality of 
choice to visualize deep CVT is MRI T1W1 [12]. Family 
history of coagulation disorders should raise suspicion 
for CVT for anyone presenting with neurological findings 
at HA. Nair et al demonstrated that PA1-1 
polymorphism lead to widespread thrombosis at 
multiple sites including aorta, bilateral iliac arteries, 
middle cerebral artery and CVT of superior sagittal sinus 
[7].
PROGNOSIS
 
The main determinant of prognosis is timely diagnosis 
and treatment. Hemorrhage is a common sequela of 
CVT and worsens clinical outcome [11]. Most cases of 
CVT show good recovery with a combination of quick 
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